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ABSTRACT 
 
This research focuses on the development and validation of a new in vitro test method capable 
of characterising realistic airway deposition of inhaled pharmaceutical aerosols, and the events 
following deposition at the airway epithelia. An existing physical model of a medium-sized 
Virginia Commonwealth University (VCU) mouth throat (MT) and tracheal bronchial (TB) 
upper airway was modified and validated to integrate Calu-3 monolayers cells cultured onto 
Snapwell® inserts for the collection of deposited drug. The model was housed in a chamber 
and validation was carried out using two nebulised ciprofloxacin formulations: a controlled-
released encapsulated liposomal solution termed “Ciprofloxacin for Inhalation” (CFI), and an 
un-encapsulated “free” solution termed “Free Ciprofloxacin for Inhalation” (FCI).  
Validation was carried out to ensure modifications to the airway model resulted in sufficient 
collection of drug for analysis, whilst ensuing minor changes to in vitro airway deposition 
behaviour. Studies were carried out to assess how experimental variables influenced in vitro 
drug permeation behaviour, i.e., choice of membrane material, formulation type and aerosol 
collection mechanism. Most importantly, the integrity of the barrier formation and tight 
junction functionality of the monolayers were assessed post airway deposition to evaluate if 
dynamic stresses caused from the airflow could affect in vivo drug transport behaviour.  
In conclusion, a novel hybrid in vitro test method has been extensively validated to successfully 
characterise realistic airway deposition of two different nebulised solutions of ciprofloxacin 
drug. It is hoped that this model can be used by others as a potential screening tool for head-
to-head comparative studies without resorting to expensive clinical trials, as well as a 
foundation for the design of new inhalation platforms with improved performance efficiency 
and reproducibility.
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CHAPTER 1  
 
Current and Emerging In Vitro Test Methods for Orally Inhaled 
Products  
To date, the development of in vitro test models used to assess the drug delivery characteristics 
of orally inhaled products (OIPs) has become a growing research trend in pulmonary drug 
delivery. With the development of novel drug formulations, coupled with advances in inhaler 
technology design, there are a range of compendial in vitro test apparatuses currently listed in 
the Pharmacopoeias intended for quality control testing of pharmaceutical inhalation products.  
Recently, such methods have been widely adapted to resemble in vivo circumstances, in attempt 
to predict airway deposition behaviour and estimate the events following airway deposition in 
vivo, i.e., drug permeation, metabolism and potential drug interferences at the airway epithelia. 
Developing robust, discriminative in vitro test methods capable of predictive outcomes is 
highly desirable; however, it has been made apparent that extensive validation is required to 
make predictive statements.  
This chapter fundamentally describes the development and advances of in vitro test methods 
and airway models used to enrich pulmonary drug delivery research. Principle decisions to find 
a suitable in vitro tool for the question being asked, i.e., from a quality control or predictive 
perspective are discussed, as well as their associated advantages and limitations. 
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1.1 Introduction 
 
The delivery of pharmaceutical medication via the pulmonary route offers significant 
advantages over systemic delivery, such as oral or intravenous administration. These 
advantages include, though are not limited to, the following key aspects: the ability to 
administer smaller doses directly to the lung, consequently mitigating adverse side effects [1, 
2]. The anatomical and histological features of the airways, i.e., large surface area for drug 
deposition in the lung, good vascularisation and thin airway epithelial lining renders rapid drug 
absorption, hence making pulmonary drug delivery a promising alternative to treat both local 
and systemic disease [3, 4]. The non-invasive nature of drug administration directly to the lung 
makes it a safer and more convenient alternative compared to intravenous administration of 
medication. 
 
The clinical response of inhaled drugs is strongly dependent on the total lung deposition and 
the associated distribution of the deposited dose throughout the region of the lung [5]. 
Deposition of inhaled aerosols throughout the lung could be understood by considering both 
the physical airway geometry and deposition mechanisms. Fundamentally, there are three main 
deposition modes which govern lung deposition: inertial impaction, gravitational 
sedimentation, and to a lesser extent, diffusion [6]. A schematic representation of these 
deposition mechanisms is illustrated in Figure 1. The air velocity in the oropharynx and large 
upper airway (including the trachea and bronchi) is relatively high compared to the lower 
airways, and so larger aerosols, typically greater than 5 μm in aerodynamic diameter, are likely 
to deposit at these regions, as well as the airway bifurcations due to their inability to follow the 
changes in air flow direction of the inspired air stream. Consequently, this may lead to 
suboptimal treatment outcomes and/or adverse effects [7, 8]. Smaller particles within the 1 to 
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5 μm aerodynamic size range have less inertia than larger particles immitted from a inhaler and 
are likely to follow the air flow direction and pass further downstream from the oropharynx 
and upper regions of the lung, possibly depositing in the bronchioles. At these regions, the air 
velocity is relatively low and deposition is likely to occur via gravitational sedimentation [6]. 
Transitioning downstream are the terminal bronchioles and alveolar region, where air velocity 
is negligible and deposition of very fine aerosols (less than 1 μm in aerodynamic diameter) 
typically occurs in a randomised fashion via Brownian diffusion. 
 
 
Figure 1. Schematic representation illustrating the main deposition mechanisms occurring at 
different regions within the airway: A) inertial impaction of larger aerosols at the upper airways 
and branched airway bifurcations, B) gravitational sedimentation of aerosols at the bronchiole 
regions, and C) random Brownian diffusion at lower airway regions. 
 
Optimal drug delivery to the lung for the treatment of local diseases such as asthma or chronic 
obstructive pulmonary disorder requires successful and consistent generation of aerosols within 
the respiratory size range: 1 to 5 µm aerodynamic diameter [7, 8]. Aerosols are generated from 
orally inhaled products (OIPs), which are a class of medical device product constituting of a 
drug formulation with one or more active pharmaceutical ingredients (API), with or without 
added excipients, delivered in either one of four different inhaler device platforms: the 
pressurised metered dose inhaler (pMDI), the dry powder inhaler (DPI), the nebuliser, and the 
more recently developed soft mist inhaler (SMI) [9-11]. With differing device designs, 
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formulation types and aerosol generation mechanisms, all inhaler platforms strive to generate 
aerosols within the respiratory size range. Table 1 shows a list of commercial inhaler platforms 
illustrating structural differences. Most nebuliser, pMDI and SMI platforms are formulated as 
solutions or suspensions that reside within the inhaler platform, and upon device actuation, 
generate fine aerosol droplets from the inhalers’ mouthpiece. On the other hand, DPIs consist 
of a dry powder either formulated in pure-drug (in micronised or as a spray dried form), or with 
a lactose carrier excipient to improve powder flowability upon device actuation. The lactose 
excipients are added to increase the dosing accuracy and minimise dose variability seen with 
most DPI formulations [12]. The breath-actuated DPIs rely on the patients’ respiratory effort 
to entrain powder from the device and break up the bulk formulation into finer particles suitable 
for inhalation while pMDI, DMI and nebulisers are active devices that impart aerosolisation 
energy to achieve a fine aerosol.  
 
Table 1. List of some commercial inhaler platform devices intended to administer 
pharmaceutical aerosols to the lung. 
 
Pressurised metered 
dose inhaler 
 (pMDI) 
- Ventolin® (suspension formulation, GlaxoSmithKline) 
- Flovent® (suspension formulation, GlaxoSmithKline) 
- QVAR® (solution formulation, Teva)  
 
Dry powder inhaler  
(DPI) 
- Pulmicort Turbuhaler® (carrier-free, AstraZeneca) 
- HandiHaler® (capsule, Boehringer Ingelheim) 
 
Nebuliser 
- Microair® NE-U22 (Mesh, Omron)  
- PARI LC® Sprint Plus, (Mesh, PARI) 
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Soft mist inhaler  
(SMI) 
- Respimat® Soft Mist (Boehringer Ingelheim) 
 
With current advances in aerosol formulation and inhaler device technology, the clinical 
performance and drug delivery efficiency of aerosols suitable for inhalation typically relies on 
the multifaceted interactions between the formulation characteristics and dispersion 
mechanisms. Therefore, assessing the extent of total lung deposition in vivo, and the 
distribution patterns of inhaled aerosols throughout the airway following device actuation, 
more so for locally-acting asthmatic drugs such as bronchodilators and anti-inflammatory 
agents, should theoretically predict their clinical effects, both beneficial and adverse [13, 14]. 
For instance, the distal small airways are the major site of air flow obstruction for patients 
suffering from chronic obstructive pulmonary disease; therefore, a lack of drug administered 
to this region could potentially contribute to poor disease control [15, 16].  
Overall, this chapter provides an integrated overview of the past, current and emerging in vivo 
and in vitro approaches used to evaluate the delivery performance of inhaled aerosols generated 
from OIPs, and its rationale in the perspective of: 
• Traditional radionuclide imaging techniques; 
• Stringent regulatory requirements for quality control practices;  
• Fundamental principles to improve and evaluate aerosol drug delivery systems; 
• Means to establish robust in vitro – in vivo correlations (IVIVCs); and,   
• Predicting the pulmonary fate following lung deposition. 
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1.2 Non-invasive radionuclide imaging techniques  
 
Traditional means to quantify in vivo lung deposition behaviour of inhaled aerosols have 
typically relied on non-invasive radionuclide imaging techniques, which can range from 
conventional two-dimensional gamma scintigraphy techniques, to more advanced three-
dimensional approaches such as single photon emission computed topography (SPECT) and 
positron emission topography (PET) [17]. Broadly speaking, such imaging techniques have 
proved to be a valuable screening platform for clinicians and researchers, providing 
information on the extent of lung deposition and regional distribution patterns in the 
oropharynx, whole lung (central, intermediate and peripheral zones) and the residual amount 
residing in the inhaler following dosing [18-21]. Such information has been used to make 
predictive statements regarding the pulmonary fate of the deposited aerosols, i.e., whether the 
deposited drug is absorbed from, cleared, or retained in the lung tissue, thereby giving 
information on the therapeutic response on the treatment regime. 
However, making predictive statements regarding the clinical response of inhaled aerosols 
based purely on in vivo lung deposition data is not straight forward. Firstly, radiolabelling of 
the drug formulation is technically challenging, and extensive in vitro validation is required to 
ensure no significant changes in formulation composition during the radiolabelling processes 
would affect drug deposition behaviour in the lung [22-24]. Furthermore, the radiolabelled 
marker must act as an adequate marker across the full range of generated aerosol sizes. 
Secondly, the amount of radioactive material must be low to minimise any risks associated 
with high radiation doses and consequently, images may suffer from poor spatial resolution 
[25]. In vivo studies are also expensive, time consuming and suffers from poor discriminatory 
power due to inter-subject variabilities, i.e., inhaler technique/usage and anatomical 
differences, make it difficult for quick and discriminative head-to-head comparisons between 
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different inhaler platforms and formulation types. For these aforementioned reasons, it is 
desirable to establish simpler and quicker test alternatives that are cost and time efficient, robust 
and sufficiently discriminative that can be used for comparative purposes, and/or make 
predictive statements on the clinical performance on the selected treatment regimes.  
Compared to imaging techniques, in vitro tests offer greater flexibility and control over 
experimental conditions in assessing how critical parameters such as formulation composition, 
or flow rate can affect overall delivery performance during the early product development 
stages. To provide such context, several different in vitro methods have been proposed, with 
strengths and weaknesses used to investigate lung deposition behaviour [26-28], and to an 
extent been developed to estimate the fate of inhaled aerosols following lung deposition i.e., 
drug dissolution, permeation and transport across the airway epithelia [29-31].  
 
1.3 Regulatory requirements for orally inhaled products 
 
The United States Food and Drug Administration (FDA) and the European Medicines Agency 
(EMA) have drafted several guidance documents intended to evaluate the overall product 
quality and delivery performance of new OIPs prior to market approval [32]. Overall, it is 
essential for manufacturers and/or developmental scientists to show that the inhaler platform 
is capable of delivering drug efficiently and reproducibility to the patient, with two essential 
parameters assessed: the emitted dose and the aerosol size distribution of the emitted dose [33-
36]; the former is an indicated of patient delivered dose and the later, regional lung deposition. 
The United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur) 
monographs have explicitly outlined a series of mandatory in vitro test procedures using 
standardised protocols, all which needs to meet specified acceptable limits before approval into 
the market [33-36]. Furthermore, such in vitro methods can be used to make head-to-head 
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comparisons between existing products, and/or used to demonstrate therapeutic equivalence 
between generic and reference products, provided satisfactory and comparative in vitro results 
[37].  
 
1.3.1 Delivered dose uniformity content  
 
For OIPs, the delivered dose uniformity content of the API and/or excipients present in a single 
delivered dose is to be evaluated across multiple batches to ensure consistent and reproducible 
dosing [38, 39]. Furthermore, testing of multiple or consecutive doses may be required from 
regulatory agents if stated otherwise. Satisfactory criterial is met from the USP monograph if: 
“ the dosage uniformity are met if not less than 9 of the 10 doses are between 75 % and 125 % 
of the label claim, and none is outside the range of 65% to 135% of the label claim”  [39]. 
Failure to comply to such specifications will result in failure to register and launch the product 
to market.  
It is important to note that testing conditions and specified general requirements listed in the 
monographs do differ between different inhaler platforms. For instance, it is required to test 
pMDIs from the mouthpiece at a fixed air flow rate of 28.3 L/min, whereas for DPIs, depending 
on the intrinsic resistance of the inhaler [40, 41], the sampled air flow rate should be selected 
such that it generates a differential pressure drop of 4.0 kPa across the inhaler, tested at a 
duration to withdraw 4.0 L of air [36]. Therefore, it is up to the manufacturer and 
developmental scientist to become acquaint with the regulatory guidelines to ensure that the 
selected test method is suitable for their final product. Additionally, dose uniformity testing is 
to be conducted throughout its’ container life, and simulated under different patient-usage 
conditions, i.e., a range of inhalation flow rates, and for (example for pMDIs) such testing 
should be conducted under simulated conditions, i.e., shaking of the canister, or sampled with 
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add-on devices (spacers and holding chambers). Potential issues pertaining to inconsistent 
dosing, such as lower-than-expected dosing may be associated with a decrease in therapeutic 
benefit, or higher-than-expected dosing may lead to an increase in unwanted side-effects, both 
being problematic from a safety and efficacy view point. 
 
1.3.2 Aerosol size and lung deposition behaviour  
 
Not only is dosing consistency a necessity from a regulatory stand point, the ability to 
demonstrate information pertaining the extent of drug deposition and distribution in the lung is 
one key characteristic that should be assessed thoroughly for OIPs. The aerodynamic size 
distribution of aerosols generated from the inhaler mouthpiece is an important parameter which 
is required from regulatory agents, and according to the Pharmacopeia guidelines “may be 
expected to correlate with the drug dose or that fraction of the drug dose that penetrated the 
lung during inhalation” [36].  
A number of Pharmacopoeia monographs have specified a list of in vitro apparatuses used to 
characterise the emitted dose in terms of aerodynamic diameter in order to obtain relevant 
sizing profiles [39, 42]. Similarly, with delivered dose uniformity, such sizing determinations 
needs to be conducted from a single dose, or multiple doses (if stated otherwise), sampled 
across multiple batches, tested throughout its container life, and simulated under different 
patient-usage conditions [39, 42]. Inconsistent sizing profiles may result in poor treatment 
outcomes particularly for locally-acting drugs, since size dictate where the aerosol deposit in 
the lung. 
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1.3.2.1 Integrating impingers and cascade impactors into the monographs  
A range of in vitro sizing apparatuses currently exist in numerous monographs. Shown in 
Figure 2, these devices range from the simple two-stage glass twin impinger (in the earlier 
British Pharmacopoeia), to the more advanced, higher resolution apparatuses, present in both 
USP and Ph. Eur. Monographs: the multi-stage liquid impinger (MSLI), the eight-stage 
Andersen cascade impactor (ACI), and the most recently developed seven-stage next 
generation impactor (NGI). All differing in designs, test specifications and tolerances, each 
apparatus consists of a series of stages, with stage consisting of a nozzle plate with one or more 
jet orifices directly positioned above an impaction plate for drug collection [43, 44]. Figure 3 
illustrates a schematic representation of the ACI demonstrating its operating principle. Upon 
testing, the emitted dose is sampled across the sizing apparatus at a constant air flow rate, where 
the dose is separated into different size fractions, depending on the inertia of the generated 
aerosols, i.e. aerodynamic diameter and aerosol velocity. Larger aerosols carrying greater 
inertia will break away from the air stream and deposit onto the impaction plate, while smaller 
aerosols will remain entrained in the air stream and pass through to the next consecutive stage, 
potentially impacting on the following surface plate. Each succeeding stage will remove a 
fraction of the emitted dose, with each stage arranged in an order of decreasing cut-off size. 
Principally, this is thought to resemble the deposition behaviour of aerosols in the lung, with 
larger aerosols depositing at the upper stages, i.e., oropharynx and large upper airways, and 
smaller aerosols depositing at the lower stages, i.e., bronchioles and alveolar regions.  
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Figure 2. List of compendial apparatuses used for routine sizing characterisation, showing the: 
A) Two-Stage Liquid Impinger, B) Multi-Stage Liquid Impinger, C) Andersen Cascade 
Impactor, and D) Next Generation Impactor [45]. 
 
                                        
Figure 3. A schematic illustration showing the operating principle and separation of aerosols 
via inertial impaction within the Anderson Cascade Impactor. Image from source: [36]. 
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The two-stage glass twin impinger operates at a calibrated, constant air flow rate of 60 L/min, 
which separates the aerosols at a pre-defined cut-off aerodynamic diameter of 6.4 µm. Given 
the reduced resolution in the size distribution within the “respirable size” range, the twin stage 
impinger may not provide sufficient information or discretionary power for adequate head-to-
head comparison. Regulatory insistence on improved separation apparatuses to obtain 
additional resolution within this size range have been advocated [33-36].  
The five-stage MSLI, calibrated at a constant air flow rate of 60 L/min separates the delivered 
dose into the following aerodynamic cut-off size diameters: stage 1 – 13.0 µm, stage 2 – 6.8 
µm, stage 3 – 3.1 µm, stage 4 – 1.7 µm, and the filth stage being the filter stage captures finer 
aerosols less than 1.7 µm [46]. The ACI is calibrated at a constant air flow rate of 28.3 L/min, 
separating the emitted dose into different size fractions ranging from 0.4 to 10.0 µm [36]. Since 
monographs specifically state pMDIs to be tested at 28.3 L/min, the ACI is an ideal test device 
for pMDI size evaluations; however, this is rather restrictive for DPIs testing since the selected 
flow rate depends purely on the intrinsic resistance of the DPI, which may not necessarily be 
targeted at 28.3 L/min [47, 48]. To resolve this dissatisfaction, the monographs have suggested 
to “omit Stage 6 and Stage 7” from the ACI impactor when sampling at air flow rates greater 
than 60 L/min [36, 42]; however, Kamiya et al have reported significant wall losses in the 
modified ACI, resulting in drastic shifts in size profiles [49]. Discussions amongst the 
pharmaceutical industry and scientists about the inadequacies pertaining current 
impingers/impactors at the time had led to the development of the NGI. The NGI was designed 
to sample aerosols at a wider range of calibrated air flow rates, i.e., from 15 to 100 L/min, 
making it ideal for nebuliser testing at very low air flow rates, to DPI sampling at higher flow 
rates [50-52]. 
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1.3.2.2 The development of the USP/Ph. Eur Induction Port  
With the array of different impingers and impactors listed in the monographs, the sizing profiles 
generated are fundamentally dependent on the overall design of the test apparatus, and the 
selected air flow rate. To ensure consistent sampling of the emitted dose into the test apparatus, 
the development of the USP/Ph. Eur induction port (IP), which is a simple, well-defined right-
angle bend serves as a standardised interface between the inhaler mouthpiece and the entrance 
of the test apparatus during routine testing of OIPs [36, 42]. A schematic illustration of the 
compendial USP/Eur IP used in conjunction with the NGI is shown in Figure 4. Additionally, 
this inlet is thought to resemble the oropharyngeal region, hence mass deposition on the 
USP/Eur IP is thought to resemble deposition in the oropharynx, in vivo.  
 
Figure 4. An illustration of the Next Generation Impactor used in conjunction with the 
USP/Eur Inlet Port, operated in A) closed form, and B) open form. Images from source: [50].  
 
1.3.2.3 Can derived-sizing parameters be used for predictive aerosol performance?  
The primary advantage of these sizing apparatuses is that direct mass measurements of the API 
can be quantified on each consecutive stage, using chemical assaying techniques such as high-
performance liquid chromatography (HPLC). Following mass quantification, critical sizing 
parameters can be derived from the generated aerodynamic size distribution profile. The most 
critical parameters commonly used for comparison purposes are the mass median aerodynamic 
diameter (MMAD), which is defined as the central tendency of the generated size distribution, 
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and the fine particle dose (FPF) and fraction (FPF), typically defined as the mass or fraction of 
the size distribution that is less than 5 μm, the fraction that resides within the optimal 
“respiratory size range” for inhalation products. Accurate determination of the aerodynamic 
size distribution profiles in impactors are paramount since it is thought to be the metric most 
indicative of lung deposition and thus in vivo outcomes. However, it is important to note that 
such impactors are limited to fractioning aerosols by aerodynamic diameter and do not 
incorporate realistic anatomy. Thus, questions such as “can induction port deposition be 
translated to make statements pertaining oropharyngeal deposition?” or “can the FPF be used 
to estimate the portion of the emitted dose that is likely to reach the smaller airways? “ need to 
be asked. Overall, these derived parameters have been used fruitfully within the pulmonary 
research field to investigate and improve the device design and formulation properties to 
increase overall delivery performance for better treatment outcomes, however direct 
relationships to predicted in vivo should always be considered with care. 
 
1.4 Establishing in vivo- in vitro methods for predictive estimates 
 
Intended for routine testing and quality control assessment, it is important to realise that 
impactor-based sizing apparatuses are not surrogates of the human airway, and that the 
operating conditions are overly-simplified, i.e., sampling the delivered dose at a constant flow 
rate as opposed to a variable inhalation profile seen with patients inhaling through their 
inhalers. Until recently, these Pharmacopoeial methods have been adopted and further refined 
as in vitro predictive models by mimicking test conditions that closely resemble in vivo 
circumstances [26, 31, 53, 54]. Ideally, if an in vitro test method could be established and 
standardised to predict in vivo behaviour for inhaled aerosols, such test methods could be 
utilised as a vital screening tool during the early product development stages. 
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1.4.1 Developing physical realistic airway models 
 
With the USP/Ph. Eur IP developed primarily to ensure consistent sampling of the emitted dose 
into the size apparatus during routine testing, it is apparent that its simplistic design cannot act 
as a physical surrogate used to mimic oropharyngeal deposition behaviour seen in vivo [55-
58]. To address this issue, researchers from the University of Alberta constructed the 
anatomically-relevant Alberta Idealised Throat (AIT) airway model cast, derived from an  
extensive database of computed tomography (CT) scans. The AIT was developed as a 
representative interface between the inhaler mouth-piece and the sizing apparatus for routine 
testing, as well to provide better air flow realisation in the oropharynx region [28]. Figure 5 
shows the structural differences between the AIT and USP/Eur IP models. The AIT is 
commercially available and is manufactured in aluminium.  
 
Figure 5. The Alberta Idealised Throat (left, in open form) and the USP/Ph. Eur induction port 
(right) [28].  
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1.4.1.1 The USP/Eur IP underestimates oropharyngeal deposition behaviour seen in vivo 
Comparative in vitro studies reported higher deposition behaviour in the AIT model to the 
compendial USP/Ph. Eur IP for a variety of commercial pMDI and DPI products [28]. The 
complex geometry of the AIT is thought to capture the coarser aerosols from the emitted dose , 
resulting in better correlation with mean in vivo lung deposition data obtained from gamma 
scintigraphy studies compared to the compendial USP/Ph. Eur IP [59, 60]. By integrating 
patient-related factors, the development of the AIT has highlighted the potential applicability 
in establishing more representative in vitro test methods used not only for routine testing for 
OIPs, but also for predictive measures on product delivery performance.  
 
 
1.4.1.2 Capturing the in vivo inter-subject variability 
For inhaled aerosols, large in vivo inter-subject variability has been reported from gamma 
scintigraphy lung deposition studies, with variations ranging from 20.0 – 60.0 % of the total 
metered dose deposited in the lung for a single test inhaler [61]. As highlighted earlier, while 
predicting and correlating mean in vitro lung deposition data to mean in vivo gamma 
scintigraphy outcomes could be established, given appropriate in vitro tools, of equal 
importance is the ability to predict the inter-subject variations that are due to apparent 
differences in airway geometries and inhalation manoeuvres [53]. 
To explore this concept further, researchers from the Virginia Commonwealth University 
(VCU) developed a “medium-sized” physical realistic upper airway model of the mouth-throat 
(MT) and tracheal-bronchial (TB) region to study realistic airway deposition in vitro [26]. The 
medium-sized MT model was constructed from CT scans based on a healthy individual adult 
[62], while the upper TB model was developed based on anatomical cast dimensions reported 
by Yeh et al [63], and for practical purposes, only extends from the trachea down to the third 
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airway bifurcation. To capture the morphological variations seen in vivo, the medium MT-TB 
airway model was volumetrically scaled to generate “small” and “large” versions of the upper 
airway in order to capture the mean and “extreme” anatomical ranges within a healthy adult 
population (Figure 6) [26]. By coupling these realistic physical airway models with 
representative inhalation profiles acquired from healthy trained patients using a breath 
simulator, the researchers were able to successfully capture this in vivo inter-subject variability 
in terms of lung deposition for a range of commercially available inhalers [26, 27].  
 
 
Figure 6. The small (left), medium (middle), and large (right) Virginia Commonwealth 
University mouth-throat and tracheal-bronchial upper airway models. The mouth-throat and 
tracheal-bronchial airway model were designed to snap-fit together to form one part [26]. 
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1.5 Is Lung Dose a Good Predictor for Clinical Response? 
 
Significant advances with representative in vitro test methods used to study and predict lung 
deposition behaviour in vivo have been sufficiently promising to make estimates on therapeutic 
outcomes for OIPs. Up to this point, it is inviting to assume that the total lung dose can be 
directly correlated with clinical outcomes; unfortunately, this assumption may be overly 
simplified. A higher total lung dose alone does not necessarily correlate to better treatment 
outcomes since the extent of local and regional deposition are of equal importance, especially 
for locally-acting drugs. For instance, if the inhaled drug is delivered at an inadequate amount, 
or to region(s) of the lung lacking target receptors, the effectiveness of the inhaled drug may 
be compromised. 
Pertaining this perspective, Longest et al proposed an in vitro – in silico approach to track 
regional lung deposition behaviour of inhaled aerosols [64, 65]. Typically, their approach 
involves measuring either the aerosol size distribution of the initial emitted dose exiting the 
inhalers’ mouthpiece, or the size distribution of the dose exiting the representative VCU MT 
model using existing compendial impactors. These measurements are then used as inputs for 
silico computational fluid dynamics (CFD) simulations used to track and quantify both local 
and regional deposition patterns of aerosol, providing an in-depth examination in the complex 
aerosol transport behaviour in the respiratory tract. Figure 7 shows a CFD simulation 
illustrating the regional deposition behaviour of aerosolised Budesonide powder emitted from 
the commercial Novolizer® DPI within the medium size VCU MT-TB airway model [65]. 
Good correlations between in silico and in vitro deposition was observed in their study. 
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Figure 7. Comparison of in vitro and in silico predictions of deposition fraction in different 
regions of the airways for the Novolizer DPI with a powdered budesonide formulation [65]. 
Of equal importance is the need to characterise the event following lung deposition, i.e., the 
dissolution and cellular transport behaviour of deposited drug occurring at the airway epithelia. 
The airway epithelium, together with the mucus layer lies at the interface between the host and 
the external environment and forms a physicochemical protective barrier against inhaled 
foreign particulate matter [66, 67]. As for many locally-acting drugs, depending on their 
solubility with the airway epithelium lining fluid, the deposited aerosols may readily be 
absorbed across the epithelium and to some extent may be redistributed in the lungs via 
clearance mechanisms (cough or via mucociliary clearance), or simply taken up by 
macrophages [1, 68]. Overall, the local bioavailability and systematic drug absorption depends 
on the fraction of deposited dose that dissolves in the lung. Hence, it is important to recognise 
the practical limitations in using in vitro lung deposition data to make predictive estimates on 
therapeutic response.  
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There has been a tremendous interest to better understand the pulmonary fate of inhaled 
aerosols following lung deposition [69-71];  that is, how do inhaled aerosols interact with the 
lung cells once deposited on the airway epithelia? How do deposited aerosols transport across 
the epithelial barrier and penetrate deep into the lung tissue? and How does aerosol size affect 
cellular uptake across the airway lining? A lot of developmental work has been forwarded to 
establish a range of in vitro test methods used to answer these questions.  
 
1.6 Current in vitro drug dissolution and release studies for inhaled aerosols 
 
Currently, there are a range of established in vitro test apparatuses and guidance documents 
used to study drug dissolution and release profiles for solid oral dosage forms and transdermal 
systems [72, 73]. There are however, no standardised Pharmacopoeial methods used to assess 
such profiles for OIPs; instead, existing methods for solid oral dosage forms have been widely 
adapted to characterise the dissolution and solubility behaviour of aerosols generated from 
inhaler devices [72, 73]. Assessing the dissolution behaviour of generated aerosols is vital to 
evaluate the efficacy of the treatment regime, since drug dissolution is a strong determinant of 
drug bioavailability and may correlate with the rate and extent of drug action at the targeted 
site.  
 
1.6.1 Current dissolution and drug release test apparatuses  
 
1.6.1.1 Rotating basket dissolution apparatus  
The rotating basket dissolution test method (USP apparatus 1) was the first official method 
used to study in vitro drug dissolution profiles for solid dosage forms. It consists of a metallic 
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drive shaft connected to a cylindrical basket where the dosage form resides, positioned within 
an enclosed hemi-spherical cylindrical vessel (Figure 8 A). Pre-warmed dissolution media is 
kept inside the vessel at a controlled temperature of 37 ± 0.5 ºC. Upon operation, the analyst 
must ensure accurate positioning of the shaft and basket in the vessel to specified test limits 
and the drive shaft rotates freely to ensure reproducible and consistent dissolution results. 
Samples are repeatedly taken from the solution vessel over time to measure drug dissolution 
into the surrounding media. 
 
1.6.1.2 Rotating paddle dissolution apparatus  
The rotating paddle dissolution test method (USP apparatus 2), similar to the USP apparatus 1 
except that the basket is substituted for a coated two-blade paddle, and the dosage form is 
positioned at the base of the vessel (Figure 8 B). By placing the dosage form freely at the base, 
several limitations are apparent with this set-up. The major limitations are adherence of drug 
to the paddle shaft and/or potential floating of the insoluble drug in the media, which can be 
collected during the sampling, significantly interfering with data reproducibility and 
consistency [74]. In an attempt to make up for some of these shortfalls, caging the dosage form 
with small, loose, non-reacting wire baskets (Figure 8 C),  or placing a mesh above the dosage 
form (Figure 8 D) have been modified into this test set-up [75]. 
Designated to evaluate the dissolution and drug release profiles for transdermal systems, the 
paddle over disk (USP apparatus 5) is identical to the USP apparatus 2, with the addition of a 
disk assembly located at the base of the vessel (Figure 8 E).  
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Figure 8. Schematic representation of the USP A) apparatus 1, B) apparatus 2, modified 
versions of apparatus 2 with C) wire basket and D) mesh, and E) apparatus 5.  
 
1.6.1.3 Reciprocating cylinder dissolution apparatus  
The reciprocating cylinder dissolution test method (USP apparatus 3) was designed based on 
the drawbacks encountered with the USP apparatuses 1 and 2 [76]. The USP apparatus 3 
consists of a set of cylindrical, flat-bottom glass outer vessels, with a set of glass reciprocating 
inner cylinders that resides within the outer vessels, attached with non-sorbing and non-reactive 
mesh screens made to fit at both ends to contain the dosage form ( 
Figure 9 A). Upon operation, the vessel is filled with dissolution media at a controlled 
temperature of 37 ± 0.5 ºC, with a motor and drive assembly used to operate the reciprocating 
cylinders vertically at a specified agitation rate (dips per minute). On the upward stroke, the 
bottom mesh in the inner cylinder moves upward to contact the dosage form, and on the down 
stroke the product leaves the mesh and floats freely within the inner tube, creating a moving 
medium. At specified time interval specified, a portion of the solution is withdrawn from a 
zone midway between the surface of the dissolution media and the bottom of each vessel. 
 
1.6.1.4 Flow-through cell dissolution apparatus  
The flow-through cell (USP apparatus 4) consists of an input pump for the dissolution medium, 
a flow-through cell compartment where the dosage form resides, and a filtration system which 
removes undissolved drug prior to sampling ( 
Figure 9 B). The bottom cone of the flow-through cell is filled with small glass beads and one 
larger bead positioned at the apex to prevent the drug from descending into the inlet tubing. 
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Upon operation, the dosage form is clamped onto the dosage holder unit and the pump forces 
the dissolution medium through the flow-through cell at a constant flow rate.  
 
Figure 9. Schematic representation of the USP apparatuses A) 3 and B) 4. 
 
 
 
1.6.2 Developing suitable dissolution test apparatuses for orally inhaled products  
 
As the aforementioned apparatuses were developed to assess in vitro dissolution and drug 
release characteristics for oral solid dosage forms and transdermal systems, several limitations 
exist when translating such methods to evaluate inhalation products. Firstly, as the therapeutic 
efficiency of inhaled products is linked to the distribution and extent of lung deposition, it is 
intuitive to study the dissolution profiles of the portion of dose that deposits in the lung, not the 
whole dose that resides in the device.  
 
To address this issue, Davies and Feddah established a novel hybrid in vitro approach to 
evaluate the effect of dissolution media composition on the dissolution rates of poorly-soluble 
inhaled glucocorticoid, administered as powdered aerosols [72]. To resemble the portion of the 
dose entering the lung, Davies and Feddah placed a glass filter downstream of the USP/Ph. Eur 
IP, attached to the ACI and sampled the emitted dose under routine compendial  procedures. 
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The collected dose was then transferred to a modified flow-through cell dissolution apparatus, 
and dissolution assessment was conducted as recommended by the guidelines [72]. Although 
this approach provided sufficient discriminatory power between different drug substances and 
dissolution media, the size fractionation capabilities of the ACI was not fully exploited; hence, 
such reported dissolution data may not necessarily reflect the dissolution profiles of fine 
particles which may be expected to deposit in the lung. To address this issue, Copley Scientific 
Limited have launched the world’s first commercially available NGI dissolution cup apparatus 
specifically designed for dissolution testing of inhaled drug formulations, a concept developed 
by Professor Jason McConville and his team at the College of Pharmacy, University of Texas. 
This test apparatus is identical to a standard compendial NGI cup, except that it has a removable 
insert in the impaction area [74]. The removable insert was designed to collect aerosols of 
known aerodynamic size, and the drug-deposited inserts are then transferred onto the disk 
assembly position in the USP apparatus 5 for routine dissolution assessment. Simple to use and 
now commercially available, the integration of the NGI dissolution cup for in vitro assessment 
of inhaled aerosols has provided better representation in terms of dissolution testing for OIPs.  
 
 
 
1.7 Cell- and tissue-based methods  
 
Up to this point, in vitro dissolution profiles for OIPs have been assessed using hybrid 
approaches, providing valuable insight on drug solubility characteristics and/or release profiles 
of deposited aerosols within the “respirable-size” range [72, 74]; however, the major limitation 
is the overall simplicity with such approaches when attempting to match in vitro data to clinical 
outcomes. Firstly, the non-representative large dissolution media used upon testing, i.e., USP 
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apparatuses 1 and 2 may involve dissolution volumes up to 900 ml to simulate dissolution of 
tablets in the stomach; however, for dissolution of inhaled aerosols at the airway epithelia, this 
large volume is not reflective of the small volume of the airway epithelium. Additionally, such 
small amounts of liquid within a stagnant environment (as opposed to the agitated environment 
established within dissolution apparatuses) may possibly inhibit drug dissolution of deposited 
aerosols, particularly for poorly water-soluble glucocorticoid drugs [72, 77]. Furthermore, the 
exact composition of the aqueous fluids and surfactant, cells and tight junctions present at the 
airway epithelia are not accurately known, and are absent during compendial USP dissolution 
testing, since synthetic, semi-permeable membranes are used as physical barriers of the 
epithelia within these test apparatuses. 
To address the aforementioned limitations, the development of in vitro cell-based models has 
been proposed to characterise drug permeation, absorption and cellular transport behaviour of 
deposited aerosols [78, 79]. Such cell-based models have been used to study the effects of gas 
concentrations, exposure time, biophysical stress, and biological agents on human airway 
epithelial cells [80]. 
Typically, this approach involves placing fresh cell culture media at the basolateral 
compartment and apically culturing cells directly onto synthetic semi-permeable membranes 
until a confluent monolayer is developed (Figure 10). Different cell-lines require different 
culturing conditions. Ideally, cell-lines should produce features of differentiated, functional 
human airway epithelial cells and contain relevant proteins and surfactants. Hence, it is up to 
the analyst to ensure and validate cultured cell lines are representative of human epithelial cells. 
Several cell-based models have been thoroughly investigated to better understand and improve 
the efficacy of treatment regimens [29, 78].  
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Figure 10. In vitro experimental set up of the call-based model cultured on Snapwell inserts 
used to assess drug permeation and absorption behaviour. 
 
1.8 Summary 
 
In vitro tests are used extensively within pulmonary drug delivery research and are recognised 
as a fundamental aspect in the development and regulation of OIPs. Currently, head-to-head 
comparison of OIPs for regulatory intentions is performed in vitro primarily by quantifying the 
total emitted dose and the generated aerodynamic size distribution using compendial impactors 
or impingers, in which derived parameters can be used to make statements on likely airway 
deposition pattern. 
 
The link between in vitro characteristics of OIPs and their clinical performance is rather 
complex. To date, the focus on developing good IVIVCs has been achieved by integrating 
patient-related factors into in vitro testing, i.e., realistic airway models and representative 
inhalation manoeuvres. However, when no correlations are established, this gives rise to 
validity issues pertaining choice of test apparatus and testing conditions. Principle decisions 
and adaptions to current methods to find a suitable in vitro tool for the question being asked 
are required (either for regulatory purposes or predictive estimates of total lung deposition), as 
well as their associated advantages and limitations do need to be addressed. Fundamentally, if 
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reliable IVIVCs could be established, then such methods could be used to simplify and cheapen  
the drug development process.  
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CHAPTER 2  
Development and Modification of the Virginia Commonwealth 
University Realistic Upper Airway Model  
This chapter describes the method development and modification of the medium-sized VCU 
MT – TB realistic upper airway model, intended for in vitro post airway deposition evaluation. 
The TB model was modified to accommodate two Snapwell® inserts above the first TB 
bifurcation region, for the collection of aerosolised drug in a more clinically-relevant airway 
model. As a proof of concept study, an in-house, high-dose aqueous solution of ciprofloxacin, 
termed Free Ciprofloxacin for Inhalation (FCI) was used as the model drug and delivered into 
the VCU MT – TB airway model using the PARI LC Sprint® jet nebuliser. Modifications to 
the TB model resulted in a minor increase in the airway deposition for nebulised FCI drug; 
however, such an increase is anticipated to lie within the expected lung deposition variation 
seen in vivo. Overall, the aerosol drug delivery system produced reproducible droplet sizes 
suitable for inhalation and enough drug was collected on the membrane inserts within the 
modified airway model for post airway deposition characterisation. Chapter 3 will describe the 
application of this modified airway model to characterise in vitro drug permeation behaviour 
following realistic airway deposition. 
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2.1 Introduction 
Compendial methods regarding in vitro tests for OIPs have relied, until present, on cascade 
impactors and impingers to measure the aerodynamic sizing properties and emitted dose 
characteristics. Data produced from these apparatuses is used to assess the delivery 
performance and provide inferences pertaining delivery performance of OIPs [81, 82]. Yet, 
deposition in the respiratory tract is the first in a series of events for a therapeutic effect to 
occur, hence relying on routine impaction procedures may not necessarily provide direct 
measurements of clinical response. There has been an increasing interest to better understand 
the pulmonary fate of inhaled aerosols following airway deposition [69-71]. That is, how do 
inhaled aerosols interact with the lung cells once deposited on the airway epithelia? How do 
deposited aerosols transport across the epithelial barrier and penetrate deep into the lung tissue? 
Unfortunately, there are currently no established compendial in vitro test methods for such 
characterisation. Recent attempts have modified the cascade impactor by introducing 
integrated epithelial cell monolayers, which have been cultured onto Snapwell® or Transwell® 
inserts of semi-permeable material to collect respirable-sized aerosols directly onto the cells in 
order to model drug transport behaviour in vitro [83, 84]. However, the main drawback with 
this hybrid impactor-cell approach is that these nozzle-based impactors are not surrogates of 
the respiratory tract, and therefore may not necessarily reflect airway deposition, drug 
dissolution and transport behaviour in vivo [85].  
There has been a growing impetus to improve on the clinical realism in OIP testing. For 
instance, the USP/ Ph Eur induction port, which is a straight 90º bend serves as the standard 
throat model used during routine testing of OIPs, have been shown to underpredict in vivo 
oropharyngeal deposition and failed to provide an accurate realisation of air flow through the 
upper respiratory tract [55, 56]. To address this issue, researchers at VCU developed and 
validated physical airway models and established in vitro test methods, to predict and capture 
Development and Modification of the Realistic Upper Airway Model 
30 | P a g e  
 
in vivo lung deposition for a range of commercial OIPs. By coupling realistic upper airway 
models with appropriate representative inhalation profiles, they were able to show a good one-
to-one IVIVC, in terms of total lung deposition for a range of commercial OIPs and were able 
to capture deposition variations seen in vivo  [86, 87]. Intuitively, lung deposition and dosimetry 
of inhaled aerosols should predict their beneficial clinical effects, since these drugs act locally 
on the airway surface, hence assessing the rate and extent of drug absorption at specific sites 
in vitro could theoretically give inferences regarding clinical outcomes. With this logic, it 
would be interesting from a research perspective, to take these established, representative 
airway models a step further and integrate cell-cultured epithelial monolayers to model in vitro 
the transport behaviour of deposited pharmaceutical aerosols. Therefore, the focus of this 
chapter describes the method development and validation procedure in modifying the 
characteristic medium-sized VCU TB airway model with cavities for the placement of 
Snapwell inserts intended to study in vitro the pulmonary fate of inhaled aerosols.  
There are three main objectives in this chapter; the first is to select a suitable drug delivery 
system that can reproducibly generate aerosols within the respirable-size range. The second is 
to evaluate if any modifications towards the VCU airway model would result in any significant 
changes in airway deposition behaviour. As previous work from Longest et al. have suggested 
less than 3 % of the total delivered dose was observed to deposit within the VCU TB airway 
model [88, 89], the last objective of this chapter is to assess if the selected drug delivery system 
can generate enough drug to be collected onto the semi-permeable inserts for drug 
quantification, and therefore be used to assess post airway deposition events.  Overall, the 
development of a modified characteristic airway model is proposed and if successful, will 
enable researchers in the field of aerosol science to better measure deposition behaviour in a 
more representative manner and consequently understand the pulmonary fate of inhaled 
pharmaceutical aerosols in vitro.   
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2.2 Materials and Methods  
 
2.2.1 Preparation and delivery of Free Ciprofloxacin for Inhalation to the realistic 
airway model 
 
2.2.1.1 Realistic airway model construction 
Stereolithography files of the characteristic medium-sized VCU MT and TB upper airway 
models were provided by the School of Engineering, Faculty of Mechanical and Nuclear 
Engineering at VCU. Airway models were manufactured as split models, constructed from a 
transparent acrylic photopolymer resin (FLGPCL02) at a layer thickness of 0.025 mm 
(Formlabs Inc, MN, USA). The MT model was made to snap fit on top of the TB model (Figure 
11). 
 
2.2.1.2 Delivery of drug to the airway model 
A high-dose, in-house aqueous FCI solution (MP Biomedical Australasia Pty Limited, NSW, 
Australia) of concentration 20 mg/mL was formulated by dissolving ciprofloxacin 
hydrochloride drug into deionised water and was used as the model drug. The selected drug 
delivery system was the PARI LC Sprint® nebuliser, used in conjunction with the PARI 
TurboBOY S compressor, supplied by PARI Medical Holding GmbH (Starnberg, Germany). 
A high-dose, continuous output aerosol drug delivery system was selected to ensure sufficient  
FCI drug collected on the Snapwell inserts for drug quantification and analysis. A custom-
made adaptor was made to attach the mouthpiece of the PARI nebuliser directly onto the 
opening of the VCU MT model. To deliver the solution into the VCU MT – TB airway model, 
the TB airway model was housed in a custom-built acrylic housing-assembly as shown in 
Figure 11 (inner diameter and height of 14.5 and 10.5 cm, respectively). An external filter 
(Suregard®, Bird Healthcare, VIC, Australia) was attached at the base of the assembly, 
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connected to a vacuum pump source (Westech Scientific Instruments, Bedfordshire, UK) to 
draw ambient air at the inlet of the airway model, at a controlled volumetric airflow rate of 15 
L/min for 90 seconds.  
 
 
Figure 11. Physical test set-up used to assess in vitro realistic airway deposition. The medium-
sized Virginia Commonwealth University mouth-throat and tracheal-bronchial airway model 
displayed in this figure was constructed of acrylonitrile butadiene styrene plastic for 
visualisation purposes [90]. 
 
2.2.2 Aerodynamic size determinations of nebulised Free Ciprofloxacin for Inhalation 
 
2.2.2.1 Aerodynamic size characterisation using the Next Generation Impactor 
Aerodynamic size characterisation of nebulised FCI drug exiting the PARI nebuliser was 
determined using the compendia Next Generation Impactor (NGI) (Westech W7, Westech 
Scientific Instruments, Bedfordshire, UK), with the standardised USP/Ph Eur induction port 
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replaced with the medium-sized VCU MT model (Figure 12).  Two millilitres of the aqueous 
solution were loaded in the reservoir of the PARI nebuliser and delivered into the NGI, at a 
volumetric flow rate of 15 L/min for a total duration 90 second. Individual NGI stages and 
VCU MT model were left uncoated. An external filter (Suregard®, Bird Healthcare, VIC, 
Australia) was connected to the outlet of the NGI to ensure complete capture of ultra-fine 
droplets less than 0.98 µm in aerodynamic diameter from penetrating the final the micro-orifice 
collector (MOC) stage as recommended by Marple et al [52]. Prior to each experiment, the 
vacuum pump was left running for 5 seconds to ensure that test conditions were established 
and stabilised within the NGI before conducting size determinations. The NGI apparatus was 
dissembled after each experiment. For mass recovery assay, the device, mouth-piece adaptor, 
VCU MT model, all stages of the NGI and external filter were rinsed using known volumes of 
deionised water and analysed using a validated ultra-fast liquid chromatography (UFLC) 
method discussed in Section 2.2.3. The MMAD, FPF (in this case, defined as droplets less than 
5.0 µm in aerodynamic diameter) and the geometric standard deviation (GSD), were 
determined using linear interpolation of the percent cumulative frequency profiles. 
The effect of droplet evaporation within the NGI were also studied by storing the NGI in the 
refrigerator overnight [91], and results compared with ambient NGI determinations (NGI not 
refrigerated). Triplicate runs were performed for both ambient and refrigerated conditions, and 
the mean was calculated for each condition.  
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Figure 12. Physical set-up of the Next Generation Impactor, with the USP/Ph Eur induction 
port replaced with the medium-sized Virginia Commonwealth University mouth-throat model.  
 
2.2.2.2 Droplet size distribution using the laser diffraction  
The droplet size distribution of nebulised FCI solution exiting the characteristic medium-sized 
VCU MT model was determined using Malvern Spraytec® laser diffraction (Malvern 
Instruments Ltd., Malvern, UK) to observe if droplet measurements, assuming generated 
droplets are spherical and approach unit density, were comparable with NGI sizing data. The 
Spraytec apparatus was setup in a vertical configuration, with the VCU MT model attached 
directly onto the sheath flow collar, to minimise the distance between the exit of the MT model 
and the measurement zone within the Spraytec apparatus, and therefore any potential droplet 
evaporation according to previous test protocols [92]. The entire assembly was a set up as a 
closed system, with a vacuum pump attached downstream to draw a controlled volumetric 
airflow rate of 15 L/min at the entrance of the MT model. Triplicate runs were performed. The 
volumetric median diameter (VMD), GSD, and corresponding FPF were determined using 
linear interpolation of the percent cumulative frequency profiles. 
 
Development and Modification of the Realistic Upper Airway Model 
35 | P a g e  
 
2.2.3 Drug quantification and data analysis  
 
Drug quantification of ciprofloxacin hydrochloride drug was performed using the Shimadzu 
Prominence UFLC system (Shimadzu Corporation, Kyoto, Japan). The system consisted of an 
SPD-20A UV-vis detector, LC-20AD liquid chromatography, SIL-20A HT Autosampler and 
Luna C-18 (2) 100A column (3µm, 150 x 4.6 mm) (Phenomenex Pty, Ltd, Lane Cove, 
Australia). Chromatography conditions were conducted using a mobile phase composition of 
methanol and 0.1 M sodium dihydrogen phosphate at a 30:70 (v/v) ratio, with pH adjusted to 
3.30 with phosphoric acid. The sampling flow rate was set to 0.8 mL/min and 20.0 µL of each 
sample was injected into the column, with the column temperature set to 40°C. Ciprofloxacin 
was detected at a wavelength of 275 nm and linearity was obtained between 0.1 and 50.0 µg/mL 
(R2 >0.999) at a mean retention time of 6.55 minutes. 
  
2.2.4 Development and modification of the realistic airway model 
 
To determine the most suitable region to place the inserts within the TB model, a clear 
transparent model of the airway was 3-D printed and the internal surface of the model was 
uniformly coated with Sar-Gel® paste (Spill Crew Corporation, NSW, Australia); a paste which 
turns purple on contact with water. Deposition of FCI droplets were carried out using the same 
set-up as shown in Figure 11. Again, 2.0 mL of FCI solution was loaded into the reservoir of a 
PARI nebuliser and delivered into the airway model at a flow rate of 15 L/min. Deposition 
patterns and regions of intense colourisation, which provided cues of deposition “hot-spots” 
within the characteristic airway model, were assessed by visualisation and considered as 
potential regions to accommodate the Snapwell inserts. Following the Sar-Gel experiments, the 
3-D printed TB model was modified to include cavities to accommodate the Snapwell inserts. 
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2.2.5 In vitro realistic airway deposition studies    
 
Realistic airway deposition experiments using the unmodified and modified airway models 
including Snapwell inserts were carried out using the set up as shown in Figure 11. Three 
millilitres of FCI solution was loaded into the reservoir of a PARI nebuliser and nebulised into 
the airway model at a controlled volumetric airflow rate of 15 L/min for a total duration of 5 
minutes. Recovery of FCI drug in the PARI nebuliser, airway model, housing-assembly and 
filter was determined using known volumes of deionised water and quantified using the UFLC 
method as discussed in Section 2.2.3. Triplicate experiments for each airway model were 
performed. 
 
2.3 Results and Discussion  
 
2.3.1 Aerodynamic size determinations of nebulised Free Ciprofloxacin for Inhalation  
 
Device retention and mass determinations of deposited FCI drug in the mouthpiece adaptor, 
MT, individual NGI stages, MOC and external filter in terms of percent total mass recovered 
collected in the ambient and refrigerated NGI are illustrated in Figure 13. Mass balance (> 95.0 
%) was obtained in all determinations. As discussed by Marple et al [52], the collection 
efficiency of stage 7 when operating at 15 L/min failed to collect some of the finer droplets 
that penetrated beyond stage 7, resulting in mass retained on the external filter. Comparable 
mass deposition of FCI drug on the VCU MT model and each consecutive NGI stage were 
observed between the refrigerated and ambient groups, indicating no droplet evaporation of the 
solution within the NGI apparatus (p>0.05, two-tailed t-test).  
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Figure 13. In vitro determinations of device retention and nebulised ciprofloxacin-
hydrochloride drug deposited on the Virginia Commonwealth University mouth-throat model 
and adaptor, and individual Next Generation Impaction stages with corresponding cut-off 
diameters. Data expressed as total percent recovered within the refrigerated and non-
refrigerated impactor, operating at an ambient airflow rate of 15 L/min for a total nebulisation 
duration of 90 seconds (n=3; mean + [SD]) [90].  
 
The percent cumulative frequency profiles of nebulised FCI droplets entering the NGI, tested 
at refrigerated and ambient conditions, were plotted as a function of midpoint aerodynamic 
diameters for the individual stages of the NGI, as well as the equivalent volumetric diameter 
distribution collected from the Spraytec diffraction data, assuming droplets are spherical in 
nature and approaching unit density. Such data is displayed in Figure 14. Derived sizing 
parameters, that is, MMAD, GSD and corresponding FPF are tabulated in Table 2. No droplet 
evaporation was evident when operating the NGI at ambient conditions, with derived metrics 
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proved to be statistically comparable between the two NGI groups (p>0.05, two-tailed t-test). 
Furthermore, the sizing profile obtained from the Spraytec apparatus were superimposed with 
NGI profiles (Table 2), with corresponding parameters being statistically comparable between 
the three groups (p>0.05, one-way ANOVA, Tukey’s Post Hoc test).  Overall, both in vitro test 
apparatuses revealed droplets being generated from the PARI nebuliser being suitable for 
inhalation purposes, with mean MMAD and GSD values being 4.77 µm and 2.25, respectively. 
Furthermore, the aerosol drug system could generate a high FPF of about 52.0 %, which is 
significantly higher than most conventional aerosol delivery systems [93, 94].  
 
Figure 14. In vitro aerodynamic size characterisation of nebulised FCI droplets exiting the 
medium-sized Virginia Commonwealth University mouth-throat model, determined using 
Spraytec laser diffraction apparatus and Next Generation Impactor when operating at 15 L/min 
for a total nebulisation duration of 90 seconds (n=3; mean + [SD]). Volumetric size data were 
converted to aerodynamic size data assuming aqueous droplets are spherical and approach unit 
density [90].  
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Table 2. Derived parameters from the Next Generated Impactor and Spraytec laser diffraction 
test apparatuses (n=3; mean ± [SD]). 
Sizing Apparatus MMAD (µm) GSD FPF (%)  
Ambient NGI  4.71 ± 0.36  2.24 ± 0.16   53.73 ± 4.42 
Refrigerated NGI 4.87 ± 0.18 2.29 ± 0.03 51.65 ± 2.13  
Spraytec a 4.74 ± 0.07 2.21 ± 0.03 52.44 ± 1.58  
a - droplets from nebulisation are assumed to be spherical and approach unit density. Therefore, VMD equals 
MMAD 
 
2.3.2 Development and modification of the realistic airway model 
 
2.3.2.1 Sar-Gel® observations 
Figure 15 shows the close-up, time-lapse deposition behaviour of nebulised FCI droplets 
depositing onto the Sar-Gel coated VCU TB airway model. Initial deposition sites first 
developed in the upper region of the TB model, after 10 seconds of nebulisation. Droplets were 
then observed above the first bifurcation region at the 30 second mark, with complete 
deposition in the airway by 60 seconds. The Sar-Gel deposition patterns of nebulised FCI drug 
revealed a similar in silico deposition trends, with most deposition occurring at the bifurcation 
region due to inertial impaction from a range of aerosol drug delivery systems [88, 89]. 
Following Sar-Gel experiments, the models were left in the laboratory for 30 minutes to test if 
the surrounding environment conditions, ~ 25 ºC at 30 – 40 % relative humidity (RH), could 
result in further colourisation within the airway model. No further colourisation was observed, 
nor any dripping of the droplets following deposition. 
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t=0 seconds t=5 seconds t=10 seconds t=20 seconds 
    
t=30 seconds t=40 seconds t=60 seconds t=90 seconds 
    
Figure 15. Close-up, time-lapse deposition patterns of nebulised FCI droplets deposited on the 
uniformly-coated Sar-Gel® medium-sized Virginia Commonwealth University tracheal-
bronchial airway model, delivered from the PARI LC nebuliser at 15 L/min [90]. 
 
2.3.2.2 Physical airway modifications 
Due to the inherently low aerosol deposition fraction previously reported in the medium-sized 
VCU TB airway model [88, 89], the choice in selecting Snapwell (Corning Life Sciences, 
polyester, pore size 0.4 µm, MA, USA) over Transwell inserts was due to the larger surface 
area  (1.13 cm2 for the Snapwell inserts, compared to 0.33 cm2 for the Transwell inserts), which 
would increase the likelihood of collecting more drug for post airway deposition analysis. Since 
deposition hot-spots occurred at the first bifurcation region in the TB airway (Figure 15), the 
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TB airway model was modified by placing a cavity above the first bifurcation region at the 
front and back, allowing for ease of  insertion and removal of the Snapwell inserts (Figure 
16B). The unmodified and modified TB airway models are shown in Figure 16. 
 
 
Figure 16. The medium-sized TB airway model: A) Unmodified and, B) Split modified version 
used in this study, with one cavity at the first bifurcation region (one at the front and one at the 
back) for the insertion and removal of the Snapwell inserts. The medium-sized TB airway 
models displayed in this figure were constructed of acrylonitrile butadiene styrene (ABS) 
plastic using fused deposition modelling 3-D printing technology (Dimension Elite, MN, USA) 
for visualisation purposes. 
 
2.3.3 Realistic airway deposition studies 
 
Mass quantification, expressed as percent total recovered dose of FCI drug retained in the PARI 
nebuliser, deposited on the MT and TB models, and ex-TB (determined by the drug recovered 
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from the housing chamber and filter) using the modified and unmodified airway models are 
shown in Figure 17. Most of the delivered dose was collected in the housing chamber and filter 
(ex-TB). No significant differences in MT deposition was observed in the unmodified and 
modified airway models, resulting in mean + SD drug deposition of 2.89 ± 0.06 and 3.13 ± 
0.14 % of the total recovered dose, respectively (p>0.05, two-tailed t-test). An increase in 
deposition was observed in the modified TB model from 1.20 ± 0.075 to 2.18 ± 0.188 % 
(p<0.05, two-tailed t-test) of the total recovered dose. It is important to note that the modified 
TB model comprises of two cavities to house the inserts within the model and were not 
completely flush with the surface, most probably affecting the overall deposition behaviour as 
observed in this study. However, it is important to realise that large variations in whole lung 
deposition have been reported in healthy human subjects, even for the same test inhaler, with 
gamma scintigraphy studies revealing high variations ranging from 20.0 – 60.0 % of the total 
metered dose for a single test inhaler [61]. Furthermore, work from Delvadia et al. [86, 87] has 
effectively captured this large variation seen in vivo by scaling the medium-size VCU MT-TB 
upper airway model to generate small and large versions, and coupling these representative 
models with clinically-relevant inhalation manoeuvres; therefore, it could be concluded that 
the observed 1.0 % increase in TB deposition in this study lies within the expected variation 
observed in vivo. Large variations seen in vivo are likely due to the range of airway geometries 
and differences in inspiratory manoeuvres between patients. The variations observed in this 
chapter are likely due to the structural changes within the modified TB airway model. 
Nevertheless, it is important to reinforce that the main aim of this study was to develop and 
modify the realistic characteristic medium-size VCU MT-TB upper airway model with 
Snapwell inserts. For our experiment, a sufficient amount of FCI drug was successfully 
collected when nebulised for a total of 5 minutes, equating to 8.2 ± 1.7 and 13.2 ± 2.2 µg of 
FCI drug deposited on the front and back Snapwell  inserts, respectively (data not shown).  
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Figure 17. In vitro deposition results of nebulised FCI drug in the unmodified (white bars) and 
modified (grey bars) airway models for a total nebulisation time of 5 minutes (n=3; mean + 
SD). Results expressed as percent total recovered dose. Ex-TB represents dose exiting the 
tracheal-bronchial airway model and is the amount collected on the housing chamber and filter.  
Asterisks (*) indicates a statistically significant difference at p = 0.05 [90].  
 
2.4 Summary 
 
This chapter describes the method development and modification of the established medium-
sized VCU TB realistic upper airway model with semi-permeable Snapwell inserts, intended 
for in vitro post airway deposition characterisation. The selected aerosol nebulisation system 
generated respirable-sized droplets, suitable for inhalation, resulting in sufficient FCI drug 
deposited onto the Snapwell inserts following realistic airway deposition.  
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Based on these results, it is possible to conclude that the use of this modified realistic airway 
model for in vitro testing of OIPs could potentially be advantageous in allowing aerosol 
researchers to better understand the pulmonary fate of inhaled drug in the airway. Chapter 3 
will discuss the next steps in utilising this modified airway model for post airway deposition 
characterisation.  
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CHAPTER 3  
Development and Validation of an In Vitro Hybrid Test Method 
used to Study Drug Permeation across Synthetic Membranes  
This chapter describes the development and validation of a novel in vitro test method intended 
to assess the permeability behaviour of deposited FCI drug across synthetic membranes, when 
nebulised into the medium-sized VCU MT and modified TB realistic upper airway model, as 
described previously in Chapter 2. Following realistic airway deposition, drug permeation 
behaviour of deposited FCI droplets were carried out using the Snapwell® test system to mimic 
the limited lining fluid volume on the lung surface. The Snapwell test system demonstrated 
reproducible and discriminatory drug permeation profiles for already-dissolved and nebulised 
FCI drug permeating across a range of synthetic membranes under different in vitro test 
conditions. The rate and extent of drug permeation depended on the synthetic membrane used, 
presence of a stirrer in the basolateral compartment and most importantly, the drug collection 
method. Although the synthetic membranes do not resemble the complex structure of the 
epithelial airway barrier, inferences regarding drug permeability behaviour for aerosolised drug 
within a representative physical airway model can be made using this novel in vitro set up. This 
approach holds great potential to evaluate other post airway deposition characteristics, such as 
particle dissolution and epithelial transport behaviour. Chapter 4 will further expand this 
approach by integrating Calu-3 monolayers on the semi-permeable inserts prior to airway 
deposition to model epithelial transport behaviour of inhaled deposited aerosols in vitro.  
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3.1 Introduction 
 
Although recent IVIVCs for OIPs have been established for lung dose estimations [86, 87], 
predicting the fate of deposited drug in the lung is rather complex [31]. Following inhalation, 
the deposited drug must dissolve onto the airway lining fluid, permeate and be transported 
across the lung tissue to achieve a clinical effect [95]. Typically, a drug effect is related to its 
concentration at the deposited site, hence it would be advantageous to monitor this 
concentration in situ; however, sampling of the lung tissue for direct measurements is not 
practical. Therefore, establishing robust and representative in vitro test methods to characterise 
the rate and extend of drug dissolution and epithelial transport behaviour for OIPs is highly 
valuable not only from design and formulation development standpoint, but also for toxicity 
and quality control purposes.  
To date, there are currently no standardised methods, nor is there a single, ideal test apparatus 
appropriate for such in vitro determinations [31, 70]. Over the past years, in vitro dissolution 
studies using compendial dissolution test apparatuses originally designed for orally-
administered solid dosage forms, namely the flow-through cell and rotating paddle apparatuses 
have been integrated and modified to study drug dissolution behaviour for OIPs [96]. For 
instance, Davis et al. have incorporated the flow-through cell apparatus, which consists of a 
reservoir and a pump that pushes the dissolution media through a flow-through cell enclosing 
the sample dose of interest, to study the effect of dissolution media composition on dissolution 
rates for a range of poorly water-soluble glucocorticoid drugs [72]. In their study, the ACI was 
used to collect aerosolised drug powder onto a glass pre-filter positioned downstream of the 
USP/ Ph Eur induction port. Although their test apparatus was able to discriminate between 
different powder formulations providing good reproducibility, their sampled dose was 
characterised as the portion of the emitted dose collected downstream from the USP/Ph Eur. 
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induction port, which is not reflective of the dose that is deposited and distributed within the 
airway. To overcome this, Son et al. took on a similar approach and placed polycarbonate filter 
membranes onto each stage of the NGI to collect aerosolised powder of relevant, pre-defined 
particles in the respiratory size range, followed by dissolution testing using the compendial 
rotating paddle apparatus [74]. As this approach allowed researchers to assess the effect of 
particle size and mass loading on drug dissolution kinetics, the main drawback with this 
approach is the significantly higher amount of dissolution media used in their study, which 
does not reflect the limited epithelial fluid lining volume in vivo [31, 69, 97]. 
Recent efforts by Arora et al. have addressed this issue by substituting the rotating paddle 
apparatus with the Transwell® system, a system intended for cellular uptake studies, to model 
and mimic particle dissolution onto, and drug permeation across the limited epithelial airway 
lining [97]. As these current and emerging methods heavily rely on cascade impactors to collect 
aerosolised drug that are within the “respirable-size” range for subsequent dissolution 
evaluations, it is important to realise that from a realistic view point, these nozzle-based 
impactors are not surrogate models of the airway, and therefore do not represent deposition 
behaviour of aerosolised drug following inhalation. With this logic, it would be intuitive to 
directly collect drug from a physical, representative airway model, followed by post airway 
characterisation using the Transwell system as a means to model dissolution onto, and drug 
permeation across the limited epithelial airway lining.  
Before any conclusive findings can be reached through in vitro methods, it is essential that the 
underlying methods are thoroughly characterised and assessed in terms of equipment design 
and experimental protocol. Hence, as a proof of concept study, this chapter provides a 
validation protocol of a novel, hybrid in vitro approach which integrates the VCU MT and 
modified TB realistic upper airway described previously in Chapter 2 to collect drug aerosols 
in a representative model, used in conjunction with the Snapwell  test system to model and 
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mimic post airway deposition behaviour for inhaled, deposited pharmaceutical aerosols. There 
are two main objectives in this Chapter; the first is to evaluate the feasibility in adapting the 
Snapwell system by assessing the permeation characteristics of already-dissolved FCI solution 
through a series of different synthetic permeable membranes, tested at static and non-static 
conditions. The second objective is to utilise the Snapwell test system to characterise and 
compare the permeation profiles of nebulised FCI droplets that have been collected onto the 
Snapwell inserts which have been placed within the modified VCU TB airway model. Overall, 
this Chapter describes the initial development and validation phases of a novel, hybrid in vitro 
approach intended to model and mimic post airway deposition behaviour in a more 
representative matter. 
 
3.2 Materials and Methods 
 
3.2.1 Preparation and delivery of Free Ciprofloxacin for Inhalation to the modified 
realistic airway model  
 
As described previously in Chapter 2, a high-dose, in-house aqueous FCI solution of 
concentration 20 mg/mL was formulated by dissolving ciprofloxacin hydrochloride powder 
(MP Biomedical Australasia Pty Limited, NSW, Australia) into deionised water and was used 
as the model drug. The physical model used to collect drug was the modified VCU MT-TB 
upper airway model (Chapter 2), consisting of two Snapwell cavities located at the first 
bifurcation region to house two Snapwell inserts (Corning Life Sciences, MA, USA) for drug 
collection. The selected drug delivery system was the PARI LC Sprint® nebuliser, used in 
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conjunction with the PARI TurboBOY S compressor and were supplied by PARI Medical 
Holding GmbH (Starnberg, Germany).  
Delivery of nebulised FCI droplets into the modified airway was achieved as described 
previously in Chapter 2. In brief, 3.0 mL of FCI solution was loaded into the reservoir of the 
PARI nebuliser, with the custom-made mouthpiece used to connect the PARI nebuliser to the 
VCU MT model. The TB airway model was housed in a custom-built acrylic housing-
assembly, with external filter (Suregard®, Bird Healthcare, VIC, Australia) attached at the base 
of the assembly, connected to a vacuum pump source (Westech Scientific Instruments, 
Bedfordshire, UK) to draw ambient air at the inlet of the airway model at a controlled 
volumetric airflow rate of 15 L/min for a total duration of 5 minutes.  
 
3.2.2 Snapwell test system for drug permeation characterisation 
 
The Snapwell system consisted of a custom-made 3-D printed miniature chamber to 
accommodate a magnetic bar stirrer (8.0 x 3.0 mm, Westlab Group, VIC, Australia) in the 
basolateral compartment. The basolateral compartment was filled with 2.3 mL of pre-warmed 
phosphate buffer saline (PBS) (Gibco, Invitrogen, NSW, Australia) to ensure complete contact 
with the basolateral-side membrane surface. The whole system was placed in a water bath 
maintained at 37 ºC. A cross-section of the Snapwell apparatus is shown in Figure 18. 
Components of the system were manufactured from a clear acrylic photopolymer resin 
(GPLCL02) (Form 2 Desktop SLA 3D Printer, Formlabs Inc, MN, USA).  
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Figure 18. In vitro experimental set up of the Snapwell test system to assess drug permeation 
behaviour.  
 
3.2.2.1 Suitability and discriminative ability of the Snapwell test system 
To assess the feasibility of the in vitro Snapwell test system, the permeation characteristics of 
FCI solution was first assessed across the standard Snapwell polyester (PE) membrane. The 
Snapwell inserts were pre-soaked with PBS up to two hours prior to permeation experiments. 
A 0.1 mL aliquot of 0.1 mg/mL FCI solution was applied directly on the apical side of the PE 
Snapwell insert which was placed in the holder chamber at time = 0. A sample aliquot of 0.5 
mL was withdrawn from the basolateral compartment at pre-determined time points over a 
period for 2 hours, with fresh pre-warmed PBS replaced immediately to maintain a constant 
volume in the basolateral chamber. At the end of each experiment, the membrane was washed 
with deionised water to recover any remaining FCI drug on top of the membrane. The influence 
of a stirred versus a non-stirred basolateral compartment on the permeation behaviour was 
investigated, with and without a magnetic stirrer. Permeation experiments were performed at 
ambient conditions (~ 25ºC at 30 – 40 % relative humidity), and each test condition were 
performed in triplicate. 
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To assess the discriminatory ability of the proposed Snapwell system, several other synthetic 
membrane materials were selected. Polyamide (PA) membranes (Sartorius™, 0.45 µm pore 
size, Göttingen, Germany) and regenerated cellulose dialysis membranes (Cellu-Sep® T2, 6-8 
kDa molecular weight cut-off, TX, USA) were the synthetic semi-permeable membranes used 
in this Chapter. Modified Snapwell inserts were created by removing the PE membrane from 
the insert and attaching either PA or a layer of a regenerated cellulose dialysis membrane onto 
the Snapwell insert. A 3-D printed ring was manufactured to attach the membrane onto the 
Snapwell insert, using a similar approach to that reported by May et al. [98]. Membranes were 
pre-soaked in PBS for two hours prior to experiments and 0.1 mL of 0.1 mg/mL FCI solution 
was applied directly onto the membrane of the modified Snapwell insert. Experiments were 
tested with and without a stirrer in the basolateral compartment and tested in triplicate. 
 
3.2.2.2 Permeation characteristics of nebulised Free Ciprofloxacin for Inhalation collected on 
the modified airway model 
To assess the permeability behaviour of nebulised FCI droplets, two standard PE or modified-
Snapwell inserts (PA and dialysis membrane inserts) were placed within the previously 
modified TB airway model prior to realistic airway deposition experiments, to collect deposited 
nebulised FCI droplets onto the synthetic membrane inserts. Prior to airway deposition 
experiments, the inner walls and internal surface of the Snapwell inserts were covered with a 
removable thin 3-D printed sheet (Form 2 Desktop SLA 3D Printer, Formlabs Inc, MN, USA) 
as recommended by May et al. [98], to allow for more accurate quantification of drug deposited 
onto the synthetic membranes. Airway deposition experiments were carried using the same 
conditions as described in Section 3.2.1. Following deposition, the two inserts were transferred 
onto the Snapwell test system to assess the permeation characteristics across the different 
membranes, with a magnetic stirrer placed in the basolateral chamber. Work from Arora et al. 
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placed additional dissolution medium on top of the drug-deposited membrane to further 
facilitate the dissolution and permeation of the collected corticosteroids particles across 
permeable membranes [99]. Henceforth, an additional subset of experiments was conducted to 
assess if the permeation of nebulised FCI droplets can be further facilitated through the 
membrane by adding 0.1 mL of deionised water on top of the drug-deposited membrane. 
Permeation experiments for each test condition were performed in triplicate.  
 
3.2.3 Drug quantification and data analysis 
 
Mass quantification of FCI drug was determined using the validated UFLC methodology 
previously described in Chapter 2. The amount of CIP-HCL drug permeating into the 
basolateral compartment was calculated by the following equation: 
 
Equation 1:  𝑚𝑡=𝑖 =  𝐶𝑡=𝑖 .𝑉𝑚𝑒𝑑𝑖𝑢𝑚 − [𝐶𝑡=𝑖−1. (𝑉𝑚𝑒𝑑𝑖𝑢𝑚 − 𝑉𝑠𝑎𝑚𝑝𝑙𝑖𝑛𝑔 )] + 𝑚𝑡=𝑖−1  
 
Where Vmedium is the volume of PBS buffer in the basolateral compartment,  
Vsampling is the sampling volume,  
Ct=i and Ct=i-1 are the drug concentration of FCI detected from UFLC at times i and i-1, 
respectively, and  
m t=i and m t=i-1 are the amount of mass released at times i and i-1, respectively.  
 
The total amount of FCI drug collected was calculated as the cumulative amount collected in 
the basolateral compartment at the end of 2 hours, plus the amount remaining on top the 
membrane.  
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3.3 Results and Discussion 
 
3.3.1 Suitability and discriminative ability of the Snapwell test system 
 
The percent cumulative mass of FCI solution permeating across the PE, PA and dialysis 
membranes into the basolateral compartment, tested under static (no stirrer) and agitated 
(stirrer) conditions are shown in Figure 19 A, B and C, respectively. It was apparent that the 
permeation behaviour of already-dissolved FCI solution differed considerably across each 
membrane. For PA, there was fast initial permeation with complete transfer of FCI observed 
after 20 minutes when tested at stirred conditions, yet slower and complete transfer was 
observed for the other membranes. This can be explained by the differences in membrane 
structure and physical interactions between the aqueous solution and the material surface. The 
aqueous solution has a better affinity to the most hydrophilic PA membrane, resulting in 
complete wetting of the solution onto the whole surface area, whereas with the tissue culture-
treated PE membrane and dialysis membranes, poorer surface wettability behaviour was 
observed at the beginning of the experiments when the solution was loaded directly on top of 
these more hydrophobic membranes, which may explain the slower and more gradual 
permeation of FCI solution across these membranes. Similarly, May et al. reported slower drug 
permeability behaviour from the PE membrane for a range of drug substances, with scanning 
electron microscopy images showing PE being less porous and having fewer permeation areas 
[98]. As expected, stirring in the basolateral compartment provided adequate mixing of FCI 
solution and PBS in the compartment, resulting in smaller experimental variability [100].   
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Figure 19. Percent cumulative mass of FCI solution permeating across the: A) Polyester, B) Polyamide, and C) Dialysis membrane inserts into 
the basolateral compartment, tested at static (empty symbols) and agitated (filled symbols) conditions (n=3; mean (error bars  are + [SD])) [101]. 
  
Validating the Snapwell Test System for Drug Permeation Characterisation  
 
55 | P a g e  
3.3.2 Permeation characteristics of nebulised Free Ciprofloxacin for Inhalation 
collected on the modified airway model 
 
The permeation behaviour of nebulised FCI droplets, collected on Snapwell inserts located at 
the front and back regions in the modified TB airway model, with or without additional water 
added, post deposition, on the PE, PA and dialysis membranes are shown in Figure 20A, B and 
C, respectively. Approximately 50 % of the deposited nebulised FCI drug permeated across all 
the tested membranes without any additional water after 2 hours of sampling, perhaps 
indicating that drug deposited as droplets on the membrane surface became dried following 
evaporation of water.  As expected, direct application water following deposition onto the 
membranes increased both the rate and extent of the permeation behaviour, with approximately 
75 – 90 % of FCI drug permeating across the membrane by the end of the experiment. It is 
thought that adding water on top of the membrane enhanced the increased dissolution on the 
donor compartment and spread of FCI drug onto the surface membrane, increasing the surface 
area coverage onto the porous areas, hence facilitating the permeation into the basolateral 
chamber. As such, the altered rate and extent of permeation may reflect a dissolution step for 
the deposited nebulised droplets on the membranes.  
 
 
 
 
 
Validating the Snapwell Test System for Drug Permeation Characterisation  
 
56 | P a g e  
 
Figure 20. Percent cumulative mass of FCI drug permeating across the front and back membranes of the: A) Polyester, B) Polyamide, and C) 
Dialysis inserts into the basolateral compartment, with (filled symbols) and without (empty symbols) additional water (n=6; mean (error bars are 
+ [SD])) [101].  
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3.4 Summary  
 
In conclusion, the development and validation of a novel, hybrid in vitro test method intended 
to characterise post airway deposition behaviour for OIPs was assessed in terms of equipment 
design and experimental protocol. As a proof of concept study, the modified, medium-sized 
VCU MT-TB airway model was used to collect nebulised FCI droplets onto semi-permeable 
Snapwell inserts within a representative airway model to mimic deposition behaviour in vivo, 
followed by drug permeation characterisation across a range of synthetic membranes. Although 
the membranes used in this Chapter do not resemble the complex structure of the epithelial 
airway barrier, the findings have illustrated how experimental factors, including, but not limited 
to the choice of permeable membrane material, presence of a stirrer and the aerosol collection 
method can significantly influence drug permeation behaviour observed in vitro.  
Chapter 4 will focus on expanding this hybrid in vitro approach to a cell-based set up, by 
integrating epithelial cell monolayers onto Snapwell inserts prior to airway deposition 
experiments.  
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CHAPTER 4 
In Vitro Characterisation of Drug Permeation and Calu-3 
Transport Behaviour for Free and Liposomal Ciprofloxacin Drug 
The development of physiologically-relevant in vitro test methods used to characterise the 
pulmonary fate of OIPs is required. This Chapter describes the development and application of 
an in vitro, cell-based representative upper airway model intended to study in vitro epithelial 
transport behaviour of two nebulised ciprofloxacin formulations: free and liposomal 
ciprofloxacin solution. Prior to realistic airway deposition, Calu-3 cell-line monolayers were 
cultured at air-liquid interface (ALI) conditions onto semi-permeable Snapwell inserts placed 
within the medium-sized VCU MT and modified TB upper airway model, as described 
previously in Chapter 2. Following airway deposition, the drug-deposited inserts were 
transferred to an in vitro Snapwell test system to mimic drug dissolution onto and epithelial 
transport into the limited airway fluid lining. In vitro drug permeation across semi-permeable 
synthetic membranes were also investigated and compared with reported transport profiles. 
The rate and extent of ciprofloxacin drug permeation and Calu-3 transport showed to be greatly 
dependent on the drug mass-concentration, formulation type, and most importantly the selected 
physical barrier used to partition the apical and basolateral compartments. The development of 
more physiologically-relevant upper airway models intended to study in vitro realistic airway 
deposition and post deposition events is vital not only from a formulation design and 
development, but also important as a tool to better understand the complex mechanisms 
underlying the pulmonary absorption of inhaled, deposited pharmaceutical aerosols. 
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4.1 Introduction  
 
The airway epithelium in the upper respiratory tract, together with the mucus layer coating its 
surface, lies at the interface between the host and the external environment, forming a 
physicochemical protective barrier against inhaled microbes, allergens and foreign particulate 
matter [66, 67]. A number of factors that help orchestrate this protective layer are the 
mucociliary escalator [102], presence of tight and adherens complex junction layers that 
regulate and control paracellular diffusion of ions and certain small molecules, associated 
transport processes via the intracellular pathway [103], and the presence of antimicrobial agents 
[104, 105]. Under the same principle, the airway epithelium may entrap inhaled therapeutic 
aerosols. For example, drugs intended for local or systematic delivery may be subjected to 
numerous clearance mechanisms such as mucociliary escalator, cough clearence, phagocytosis 
by macrophages, absorption across the epithelium and metabolism imto non-active related 
substances, all possibly reducing the overall efficacy and therapeutic ratios of the treatment 
regimen [1, 68].  
For instance, low tissue permeability is typically necessary for locally-acting drug intended to 
treat respiratory disorders in the upper respiratory tract, since rapid absorption into the 
bloodstream will reduce the drug’s ability to render a therapeutic effect at the targeted site, 
potentially resulting in unwanted systemic side effects if absorbed readily [106]. Longer lung 
retention of inhaled drug may also be desirable for slow, controlled-release formulations, i.e., 
inhaled antibiotics where the therapeutic dose may be lowered compared to oral or parenteral 
doses, therefore potentially minimising drug resistance [107] and the time at which an 
minimimum bacterisocidal concentration locally is increased. On the other hand, the 
therapeutic profile for inhaled drugs intended for systematic delivery (for example in some 
peptides and proteins) is dictated by the absorption characteristics at the epithelia. Drug 
absorption behaviour depends on an array of factors: type of formulation (solution or 
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suspension), droplet or particle size properties, mass-concentration at the deposited site, and 
the physicochemical properties of the molecule (i.e. intrinsic solubility, LogP, acidic and basic 
nature) and the physical state upon contact with the airway epithelium [95, 108]. For instance, 
inhaled drugs that are in complete solubilised form, will passively diffuse across the epithelia 
intracellularly, or be transported paracellularly, becoming available for absorption [109]. 
Conversely, poorly water-soluble drugs may experience incomplete dissolution onto the 
epithelial liquid lining, and are more likely to be retained in the lung for longer periods; 
therefore having a greater chance of being removed from the lungs by mucociliary clearance 
or cough [110]. As such, the development of representative in vitro epithelial barrier models 
intended to mimic these complex interactions between drug carriers, active ingredients at the 
epithelia will help researchers understand the complex mechanisms underlying the pulmonary 
absorption of pharmaceutical aerosols.  
To date, the development and use of in vitro cell-based culture models as reconstructed barriers 
of the epithelium offers greater simplicity, reproducibility, and better control over experimental 
parameters compared to isolated perfused organs and use of animal tissue [111-113]. When 
developing in vitro epithelial cell-based culture models, the selection of either primary cells or 
immortalised cell-lines is presented, each with their associated strengths and weaknesses [114, 
115]. Typically, primary cell cultures endure major limitations due to lack of availability or 
access to normal human airway tissue by researchers, long and complicated cell culture 
processes, and large variations between donors. Immortalised cell-lines on the other hand have 
been manipulated to undergo ‘indefinite’ cellular division in culture, making them more 
reproducible, homogeneous and readily available [116]. Derived from bronchial 
adenocarcinoma tissue, the immortalised Calu-3 cell-line is a well-differentiated and 
characterised in vitro cell model and that is considered to be representative of the bronchial 
epithelium in terms of expression of tight intercellular junctions and secretory proteins. These 
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cells have been extensively used to study in vitro pulmonary absorption for a range of OIPs 
[29, 78]. To create a representative barrier of the epithelia, Calu-3 cells can be cultured onto 
semi-permeable Transwell or Snapwell cell-culture inserts to form tight, confluent monolayers 
[79, 116, 117]. There are two methods to culture confluent Calu-3 monolayers onto these 
membranes, either in an air interface culture (AIC) or liquid covered culture (LCC) condition. 
for aerosol/particle related studies AIC is generally considered more relevant and is 
morphologically representative of the airway epithelium [29, 118].  
For this reason, the overall aim of this Chapter, is to extend the in vitro hybrid methodology 
previously described in Chapter 3 to a representative bronchial epithelial cell -based culture 
model, intended to mimic and study realistic deposition, drug dissolution into and consequent 
Calu-3 transport behaviour across the confluent monolayer within a physical realistic airway 
model. This was achieved by first culturing Calu-3 cells onto semi-permeable Snapwell cell 
culture inserts under ALI conditions, which were then placed in the modified medium-sized 
VCU TB airway model prior to realistic airway deposition studies.  
Overall, four study aims are presented in this Chapter:  
(1) The first aim was to evaluate and compare in vitro Calu-3 transport behaviour of two 
nebulised ciprofloxacin formulations: a controlled-released encapsulated liposomal 
nanoparticle solution and an aqueous, free solution of ciprofloxacin drug. As ciprofloxacin is 
a well-established broad-spectrum fluoroquinolone antibiotic used to treat infectious bacteria 
[119, 120], the encapsulation of ciprofloxacin drug to treat respiratory infections in the lungs 
could potentially be more advantageous compared to unencapsulated free drug, since drug 
release profiles are slower and sustained at deposited targeted sites, resulting in safer and lower 
dosing frequencies and therefore reducing overall systematic side effects. As such, the first aim 
was to assess how a different formulation type may influence in vitro drug transport behaviour.  
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(2) The second aim was to evaluate the effect of drug mass-concentration on in vitro drug 
transport behaviour, by varying the total nebulisation time to deposit different amounts of 
ciprofloxacin drug onto the Calu-3 monolayer. Extending this aim, it was hypothesised that the 
dynamic airflow within the airway model may potentially induce shearing stresses on the Calu-
3 monolayer, which could affect the barrier integrity and tight junction functionality of the cell -
line monolayer.  
(3) Following on from aim two, the third aim was to characterise any changes in the barrier 
integrity and tight junction properties by assessing the trans-epithelial electrical resistance 
(TEER) and apical-to-basolateral flux of the paracellular tracer molecule Fluorescein-Sodium 
(Flu-Na) following Calu-3 transport of both formulations at different mass-concentrations.  
(4) Lastly, drug permeation behaviour for both formulations was assessed across different 
semi-permeable synthetic membranes and compared to reported Calu-3 transport behaviour.  
 
Overall, this Chapter describes the extension and application of a novel, morphologically 
representative in vitro cell-based model intended to better understand the complex mechanisms 
underlying the pulmonary absorption of OIPs. 
 
4.2 Materials and Methods 
 
4.2.1 Preparation of Free and Liposomal Ciprofloxacin solution formulations 
 
As described previously in Chapter 2, a high-dose, in-house aqueous FCI solution of 
concentration 20 mg/mL was formulated by dissolving ciprofloxacin hydrochloride powder 
(MP Biomedical Australasia Pty Limited, NSW, Australia) into deionised water and was used 
as the model drug used in this Chapter. For comparison purposes, Lipoquin®, termed 
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Ciprofloxacin for Inhalation (CFI) is a controlled-released liposomal formulation consisting of 
ciprofloxacin nanoparticles encapsulated in unilamellar liposomes, and was kindly provided 
by Aradigm Corporation (Hayward, CA, USA). In brief, multilamellar liposomes were formed 
by completely dissolving a mixture of hydrogenated soy phosphatidylcholine and cholesterol 
with mixture of t-butanol, ethanol and water, followed by mixing with ammonium sulphate 
[119]. This liposomal mixture was then extruded through 80 nm filters to yield unilamellar 
liposomes, and ciprofloxacin drug was actively loaded to the unilamellar liposomes [119, 121]. 
Unencapsulated ciprofloxacin drug was removed, resulting in an encapsulation efficacy of 
ciprofloxacin drug greater than 99.0 %, at a total target concentration of 50 mg/mL [119]. For 
comparison purposes, CFI was diluted from 50 mg/mL in sodium acetate buffer (25 mM 
sodium acetate, 145 mM sodium chloride at adjusted pH of 4.0) to a final concentration of 20 
mg/mL per protocol [122].  
 
4.2.2 Physical barriers used to model in vitro drug transport and permeation  
 
4.2.2.1 Calu-3 air-liquid interface cell-line for in vitro drug transport studies  
The immortalised bronchial adenocarcinoma Calu-3 cell-line was purchased from American 
Type Culture Collection (ATCC HTB-55, Manassas, VA, USA) and was cultured onto semi-
permeable Snapwell cell culture inserts (1.13 cm2, polyester membrane, 0.4 μm pore, Corning 
Life Sciences, MA, USA) to model epithelia transport behaviour in vitro. Calu-3 cells were 
used between passage 40-43 and cultured in 75 cm2 tissue culture flasks (Corning® Costar®, 
Corning Life Sciences, MA, USA), cultured in Dulbecco’s Modified Eagle’s medium: Nutrient 
Mixture F-12 (DMEM:F12, Sigma-Aldrich, Sydney, NSW Australia) without phenol red and 
L-glutamine, including sodium bicarbonate and 15 mM HEPES, and supplemented with 10 % 
(v/v) fetal calf serum, 1 % (v/v) non-essential amino acid solution, and 1 % (v/v) ʟ-glutamine 
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solution (200mM) (Invitrogen, Sydney, Australia). Calu-3 cells were grown at 37°C in 5% CO2 
and media was changed every 2 days until confluence was reached. Calu-3 monolayers were 
grown on the apical side of the Snapwell inserts at seeding density 1.65 x 106 cells/well in 200 
µL apical and 2 mL of DMEM:F12 media in the basolateral compartment. The apical media 
was removed after 2 days to establish ALI conditions, with media changed every second day. 
The monolayers were allowed to differentiate under ALI conditions until confluency reached 
at day 11. 
 
4.2.2.2 Synthetic membranes for in vitro drug permeation studies  
Since the amount collected into the basolateral compartment must first be transported across 
the Calu-3 monolayer and then permeate across the semi-permeable synthetic polyester 
membrane of the Snapwell insert, separate in vitro drug permeation experiments, for both FCI 
and CFI formulations, were repeated without culturing the Calu-3 cell-line on the membrane, 
to account for any membrane effect on in vitro transport behaviour.  
Additionally, since the polyester membrane contain pore sizes of 0.4 µm in diameter, to model 
the release of encapsulated drug nanoparticles from the liposomes (approximately 80 nm in 
diameter [119]), followed by permeation of the released encapsulated nanoparticles across the 
synthetic membrane, additional permeation experiments were repeated across a layer of a 
regenerated cellulose dialysis membrane (Cellu-Sep®, Regenerated Cellulose Tubular 
Membrane, 6-8 kDa molecular weight cut-off). The polyester membrane was replaced with a 
dialysis membrane layer by mounting the dialysis membrane onto the insert using a custom-
made 3-D printed ring as previously described in Chapter 3.  
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4.2.3 Delivery of Free and Liposomal ciprofloxacin to the modified realistic airway 
model 
 
The physical airway model used to deliver both ciprofloxacin formulations was the modified 
medium-size VCU MT-TB upper airway model previously described in Chapter 2. This airway 
model was modified at the first TB bifurcation region (front and back regions) to accommodate 
two cavities were Snapwell inserts were located. The MT and TB airways were made to snap-
fit together, and the TB model was housed in a custom-built acrylic housing-assembly, with an 
external filter (Suregard®, Bird Healthcare, VIC, Australia) attached at the base of the 
assembly, connected to a vacuum pump (Westech Scientific Instruments, Bedfordshire, UK) 
to draw ambient air at the inlet of the airway model, at a controlled volumetric airflow rate of 
15 L/min. 
The aerosol drug delivery system used in this Chapter was the PARI LC Sprint® nebuliser, used 
in conjunction with the PARI TurboBOY S compressor, supplied by PARI Medical Holding 
GmbH (Starnberg, Germany). Prior to airway deposition, Calu-3 cell-culture inserts or 
synthetic inserts were placed within the modified TB airway model, using the experimental 
set-up as described in Chapter 3. In brief, 3.0 mL of either FCI or CFI solution was loaded into 
the reservoir of the PARI nebuliser using a custom-made mouthpiece to connect the PARI 
nebuliser to the opening of the VCU MT model. To deposit different amounts of ciprofloxacin 
onto the inserts, the total nebulisation times investigated were 1 minute and 3 minutes to assess 
the effect of drug mass-concentration on in vitro drug transport and permeation behaviour  
across the cell-line.  
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4.2.4 Drug permeation and transport following realistic airway deposition  
 
Following airway deposition of FCI and CFI solution into the modified airway model, the 
nebulised drug was left to settle within the model and housing chamber up to 2 minutes before 
detachment to prevent any loss of drug to the surrounding environment. The modified TB 
airway model, which either housed the Calu-3 cultured Snapwell inserts or the synthetic inserts, 
was disassembled and the drug-deposited inserts transferred to the standard Snapwell system 
(Corning® Costar®, Corning Life Sciences, MA, USA), without a stirrer in the basolateral 
chamber to mimic drug dissolution into and permeation and transport of deposited droplets 
across the airway liquid lining, as opposed to methodology described in Chapter 3. Given the 
small clearance between the cell monolayer and base of the chamber, the stirrer was removed 
in this experimental set up as it may result in contact with the monolayer, possibly disrupting 
the physical barrier. The basolateral compartment was filled with 1.0 ml of either pre-warmed 
Hank's Balanced Salt Solution (HBSS) buffer (Sigma-Aldrich, Sydney, NSW Australia) for 
drug transport studies, or PBS buffer (Sigma-Aldrich, Sydney, Australia) for drug permeation 
studies. The whole Snapwell system was placed in a well-controlled incubator maintained at 
5% CO2 at 37°C to mimic stagnant humid in vivo conditions. Frequent aliquots of 200 µL were 
sampled from the basolateral compartment at pre-determined time points over 4-hours, with 
fresh, pre-warmed PBS/HBSS replaced immediately to maintain a constant volume. For CFI 
studies, complete recovery of encapsulated ciprofloxacin drug was achieved by diluting the 
sample aliquot with 80:20 (v/v) methanol:water as described by Ong et al [123]. For drug 
permeation experiments, the apical compartment was washed with water to recover any 
remaining drug at the end of 4 hours, or in the case with CFI, further diluted with 80:20 (v/v) 
methanol:water. For drug transport studies, the monolayer was firstly washed with known 
volumes of HBSS buffer to quantify the remaining drug left on the cell surface, and in the case 
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with CFI, the sample was further diluted with 80:20 (v/v) methanol:water. To quantify the 
amount of drug remaining intracellularly, the monolayer were removed and trypsinated from 
the membrane using trypsin-EDTA solution (2.5 g/L trypsin, 0.5 g/L EDTA, Invitrogen, 
Australia) and left on the monolayer for 5 minutes, subsequently lysed in CelLytic™ M Cell 
Lysis reagent in the presence of 1% (v/v) protease inhibitor cocktail, on ice according to a 
published protocol from Ong et al [84]. Lysates were centrifuged at 10,000 g for 10 minutes at 
4°C [84], and the supernatant was aspirated and diluted to an appropriate volume for drug 
quantification using a validated UFLC methodology as described in Section 4.2.5. 
 
4.2.5 Drug quantification and data analysis 
 
The chromatography conditions for mass quantification of ciprofloxacin-hydrochloride drug 
was determined as described in Chapter 2. Calculations in the amount of drug being transported 
and permeated into the basolateral compartment is similarly determined in Chapter 3. The 
initial mass of drug deposited on the Snapwell inserts was calculated by determining the 
cumulative mass of drug collected in the basolateral compartment at the end of 4-hours, plus 
the amount remaining on the apical compartment. Drug transport or permeation profiles of both 
FCI and CFI were described as cumulative mass of drug being transported across the Calu-3 
monolayer, or permeated across the synthetic membrane, into the basolateral compartment as 
a function of time. The statistical profile comparison employed either unpaired, two-tailed t-
test or one-way analysis of variance (ANOVA), where results were found to be significantly 
different based upon 95% probability values. 
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4.2.6 Barrier integrity and tight junction functionality of the calu-3 monolayer  
 
4.2.6.1 Trans-epithelial electrical resistance measurements of Calu-3 monolayers post-
transport studies  
To assess if the dynamic airflow exposure to cells following 1-minute and 3-minutes 
nebulisation within the airway model induced any shearing stresses onto the Calu-3 monolayer, 
the barrier integrity and tight junction functionality following post 4-hour transport studies of 
FCI and CFI deposition was assessed by TEER measurements using an epithelial voltohmmeter 
(EVOM) with chopstick electrodes (World Precision Instruments, Sarasota, FL, USA). TEER 
readings were measured by the electrical resistance across the monolayer, which is an indirect 
measure of tight junction functionality, where higher TEER readings indicate tighter junctions.   
For TEER measurements following transport studies, the drug-deposited Snapwell inserts were 
transferred to a new Snapwell system which contained fresh, pre-warmed HBSS buffer in the 
basolateral compartment. Fresh 200 µL of HBSS buffer was then added on the apical 
compartment, and the system was equilibrated for 30 minutes in a humidified atmosphere at 
5% CO2 at 37°C. TEER measurements for each Snapwell were measured at 3 different 
locations. Raw TEER data were corrected by subtracting measurements with the average TEER 
measurements from blank polyester Snapwell insert and multiplied by the surface area of the 
membrane (1.13 cm3). TEER measurements for control (without nebulisation) were carried out 
for comparison purposes.  
4.2.6.2 Paracellular permeability of fluorescein-sodium across Calu-3 monolayers 
The apical-to-basolateral flux of the tracer molecule Flu-Na (molecular weight 0.367 kDa, May 
& Baker Ltd. Dagenham, England) across the Calu-3 monolayer dictate the movement of small 
molecules via the paracellular route [124]; hence, flux comparison of Flu-Na across the 
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monolayer following 4-hour drug transport studies were carried out and compared to control 
to assess any real differences in permeability behaviour as a result of nebulisation. Following 
TEER measurements, the HBSS buffer on the apical compartment was removed and 200 µl of 
2.5 mg/mL Flu-Na solution was applied directly onto the apical compartment. At pre-
determined time points, 100 µL aliquots were sampled directly from the basolateral 
compartment over 1 hour, with fresh HBSS replaced to maintain a constant volume in this 
compartment. Sample aliquots were diluted into HBSS and fluorescence of Flu-Na was 
measured using a black 96-well plate via SpectraMax M2 microplate reader (POLAR star 
Optima, VWR International, Leicestershire, UK) at excitation and emission wavelengths of 
485 nm and 520 nm according to Ong et al [115]. The apparent permeability coefficient (Papp) 
was calculated according to the following equation: 
 
Equation 2:  𝑃𝑎𝑝𝑝 = 𝑉 𝐴𝐶𝑜⁄
. 𝑑𝐶 𝑑𝑡 ⁄ d 
 
where V is the volume of HBSS buffer in the basolateral chamber 
A is the surface area of the Snapwell membrane (1.13 cm2) 
C0 is the initial concentration of Flu-Na in the apical compartment (μg/mL) and  
dC/dt is the flux (rate of change in Flu-Na concentration measured in μg/mL/sec) 
Units for Papp coefficient are in cm/sec.  
 
Standards of Flu-Na solution were confirmed between 0.125 and 12.5 µg/mL with a coefficient 
of determination greater than 0.999. 
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Results and Discussion 
 
4.2.7 Barrier integrity and tight junction functionality of the calu-3 monolayer  
 
Mean (SD) of reported TEER measurements for both nebulised groups exposed to 1-minute 
and 3-minutes nebulisation of FCI and CFI drug, and the corresponding Papp of Flu-Na 
following 4-hour drug transport studies, are illustrated in Figure 21 A and B, respectively. With 
respect to the control group, a significant decrease in TEER was observed when nebulising 
both solutions into the airway model for a duration of 3 minutes, irrespective of the formulation 
type (Figure 21 A) (p<0.05, one-way ANOVA, Dunnett's Post Hoc test), resulting in a decrease 
in TEER measurements from 974.6 ± 187.5 Ω.cm2 (control group) to 445.9 ± 210.6 and 462.3 
± 55.98 Ω.cm2 for FCI and CFI, respectively. No significant decreases in TEER was observed 
when nebulising both ciprofloxacin formulations for 1 minute, compared to control (600.5 ± 
110.0 and 612.6 ± 57.1 Ω.cm2 for FCI and CFI, respectively; p>0.05, one-way ANOVA, 
Dunnett's Post Hoc test). Furthermore, no significant differences in TEER measurement were 
also observed between both formulations when tested at both nebulisation conditions (p>0.05, 
unpaired, two tailed t-test), thus indicating that the nebulisation duration being the stronger 
variable influencing TEER measurements in comparison to formulation type.  
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Figure 21. In vitro results showing: A) Trans-epithelial electrical resistance (TEER) 
measurements and, B) derived Papp coefficients of Flu-Na flux permeating across the Calu-3 
cell monolayer post 4-hour transport studies following 1-minute and 3-minutes nebulisation of 
Free Ciprofloxacin for Inhalation (FCI) and Ciprofloxacin for Inhalation (CFI) formulations 
(n≥3; mean ± [SD]); Statistical analysis was performed using one-way ANOVA, Dunnett's Post 
Hoc test; * p < 0.05; ** p < 0.01.   
 
Calculated Papp values showed no significant differences compared to the control group 
irrespective of nebulisation duration and formulation type (p>0.05, one-way ANOVA, 
Dunnett's Post Hoc test), indicating intact monolayers with functional tight junctions (Figure 
21 B), despite the observed decrease in TEER measurements following 3-minutes nebulisation. 
However, it is important to realise that TEER is a measurement of electrical resistance across 
the cell monolayer, which is a simple and indirect method used to assess epithelial monolayer 
formation and integrity, rather than differences in paracellular permeability, or characteristic 
changes in pore sizes across cell-cultured monolayers using paracellular markers such as Flu-
Na [125, 126]. To add to this argument, the total amount of drug deposited on the monolayer 
was hypothesised to be a confounding factor in this Chapter, as a two-fold increase in deposited 
mass was observed when nebulising for longer durations. However, a previous study from Ong 
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et al has illustrated that for both FCI and CFI solution formulations, no detrimental effects on 
the Calu-3 monolayer when ciprofloxacin droplets deposited Calu-3 monolayers, provided the 
total mass of ciprofloxacin drug collected was less than 20.0 µg [123]. In this Chapter, the total 
mass of ciprofloxacin drug deposited on the Calu-3 monolayer following 3-minutes 
nebulisation was less than 7.0 µg (as discussed below), substantiating that the drug mass-
concentration due to total nebulisation duration does not have a confounding effect on cellular 
barrier integrity. With this logic, direct Papp measurements may be a more sensitive and reliable 
method used to confirm the integrity and permeability of deposited drug across the monolayer, 
despite observing a significant reduction in TEER when monolayers are exposed to the ambient 
air upon longer nebulisation times.  
 
4.2.8 In vitro drug permeation and transport following realistic airway deposition  
 
4.3.2.1 In vitro calu-3 transport behaviour of nebulised ciprofloxacin droplets 
Cumulative mass profiles of both FCI and CFI droplets transporting across the Calu-3 cell 
monolayer following 1-minute (circle symbol) and 3-minutes (square symbol) nebulisation into 
the modified airway model are shown in Figure 22 A and B, respectively. Overall, faster drug 
transport was observed with increasing dose of both formulations, indicating that the drug 
mass-concentration was the rate-determining step for in vitro Calu-3 transport. For the FCI 
formulation, approximately 0.74 and 1.90 µg of ciprofloxacin drug was transported by the 4-
hour mark when nebulised for 1-minute and 3-minutes, respectively, corresponding to 
approximately 43.3 and 47.5 % of the total mass collected, respectively. On the contrary, the 
CFI formulation resulted in significantly slower transport behaviour compared to FCI, with 
only 0.60 and 0.90 µg ciprofloxacin drug being transported by 4-hours when nebulised at 1-
minute and 3-minutes, respectively, corresponding to 23.5 and 13.7 % of total mass collected. 
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The effect of drug mass-concentration was less evident for CFI, as the cumulative amount 
transported by 4 hours found to be comparable (p>0.05, unpaired, two tailed t-test). This slower 
rate of drug transport was expected for CFI, since encapsulated nanoparticles first must be 
released from the liposomes, and then be transported across the Calu-3 cell-line to be sampled 
from the basolateral compartment.  
 
 
Figure 22. Cumulative mass transport profiles as a function of time following 1-minute (circle 
symbols) and 3-minutes (square symbols) nebulisation for: A) Free Ciprofloxacin for 
Inhalation (FCI) and, B) Ciprofloxacin for Inhalation (CFI) droplets transporting across the 
Calu-3 cell monolayer, respectively, collected within the modified Virginia Commonwealth 
University tracheal-bronchial airway model (n≥3; mean + [SD]). Legend displays 
corresponding mean (±SD) masses collected at both nebulisation times. 
 
A previous study by Ong et al were able to show using live-cell confocal microscopy imaging 
techniques an uneven distribution of nebulised CFI droplets across the Calu-3 monolayer and 
slower diffusional spreading compared to FCI, which additionally explains the slower transport 
behaviour of CFI reported in this Chapter [123]. For both formulations, faster transport of drug 
was observed with increasing mass and this was more apparent for FCI (Figure 22A), indicating 
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that the drug mass-concentration being the rate-determining step for in vitro drug transport 
behaviour. However, since monolayers are cultured onto synthetic PE membranes, to account 
for any membrane effect on in vitro transport behaviour, separate drug permeation experiments 
were repeated across the synthetic, semi-permeable polyester membrane of the Snapwell insert, 
tested under the same conditions. 
 
4.3.2.2 In vitro drug permeation behaviour of nebulised ciprofloxacin droplets across synthetic 
membranes  
Corresponding cumulative mass profiles of FCI and CFI droplets permeating across the 
polyester membrane following 1-minute (circle symbol) and 3-minutes (square symbol) are 
shown in Figure 23 A and B, respectively. Irrespective of total mass collected on the polyester 
membranes, cumulative mass profiles appeared to be comparable for FCI, resulted in 
approximately 2.10 and 2.12 µg of ciprofloxacin drug permeating across the polyester 
membrane by the end of 4 hours, when nebulised at 1-minute and 3-minutes, corresponding to 
63.2 and 31.5 % of the total mass collected, respectively. This indicates that the synthetic 
polyester membrane, not the drug mass-concentration was the rate-determining step driving in 
vitro drug permeation of ciprofloxacin drug into the basolateral compartment. A similar effect 
was observed with CFI, with comparable amounts permeated by the end of 4 hours (p>0.05, 
unpaired, two tailed t-test). Approximately 2.0 and 2.6 µg of ciprofloxacin drug was permeated 
across the polyester membrane when nebulising CFI solution for 1-minute and 3-minutes, 
respectively, corresponding to 48.3 and 38.0 % of total mass collected).  
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Figure 23. Cumulative mass permeation profiles as a function of time following 1-minute 
(circle symbols) and 3-minutes (square symbols) nebulisation, permeating across the synthetic 
polyester membrane for: A) Free Ciprofloxacin for Inhalation and, B) Ciprofloxacin for 
Inhalation droplets, respectively, collected within the modified Virginia Commonwealth 
University tracheal-bronchial airway model (n=4; mean + [SD]). Legend displays 
corresponding mean (±SD) masses collected at both nebulisation times. 
 
Even though the use of synthetic membranes does not resemble the complex structure of the 
airway epithelium, inferences regarding in vitro drug release and permeability characteristics 
for slow, controlled release formulations can be inferred, depending on selected membrane. 
For instance, in vitro drug permeation for both FCI and CFI droplets appeared to be comparable 
across the polyester membrane, though a more discriminating capability, in terms of in vitro 
drug release and transport behaviour for both FCI and CFI formulations was observed across 
the Calu-3 monolayer (Figure 22). This lack in discriminative ability using the polyester 
membrane can be attributed to the relatively larger pore sizes, i.e., 0.4  µm, compared to 
reported unilaminar liposomes vesicle size ranges, i.e., 80-90 nm [122], potentially resulting in 
unilaminar liposomal vesicles which contain encapsulated ciprofloxacin nanoparticles 
permeating across the polyester membrane before the nanoparticles could be released from the 
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liposomes. As such, the polyester membrane proved to be inadequate to membrane model in 
vitro release behaviour of encapsulated drug from CFI in this Chapter.  
To address this non-discriminating ability, further in vitro drug permeation experiments were 
carried out by replacing the polyester membrane with a layer of regenerated cellulose dialysis 
membrane, which partitions solutes based on their molecular cut off weight (6-8 kDa) instead 
of physical size. The cumulative mass profiles of FCI and CFI drug permeating across the 
dialysis membrane following 1-minute and 3-minutes nebulisation are illustrated in Figure 24 
A and B, respectively.  
In vitro drug release and permeation behaviour was more distinct between both formulations 
using the dialysis membrane, with a slower permeation behaviour seen with CFI as 
nanoparticles first must be released from the liposomes to be permeated across the dialysis 
membrane. For FCI, the drug mass-concentration appeared to be the rate-determining step for 
in vitro drug permeation, with approximately 1.42 and 2.44 µg of ciprofloxacin drug 
permeating across the dialysis membrane when nebulised at 1-minute and 3-minutes equivalent 
to 37.9 and 40.6 % of the total mass collected, respectively. This mass-concentration rate-
determining effect was less evident for CFI drug, with comparable amount of ciprofloxacin 
drug being permeated by the end of 4 hours (p>0.05, unpaired, two tailed t-test), resulting to 
approximately 1.09 and 0.85 ug of drug permeated across the dialysis membrane when 
nebulised at 1-minute and 3-minutes, respectively, corresponding to 30.6 and 10.4 % of total 
drug collected.  
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Figure 24. Cumulative mass permeation profiles as a function of time following 1-minute 
(circle symbols) and 3-minutes (square symbols) nebulisation, permeating across the dialysis 
membrane for: A) Free Ciprofloxacin for Inhalation and, B) Ciprofloxacin for Inhalatio n 
droplets, respectively, collected within the modified Virginia Commonwealth University 
tracheal-bronchial airway model (n≥3; mean + [SD]). Legend displays corresponding mean 
(±SD) masses collected at both nebulisation times. 
Overall, the polyester membrane demonstrated comparable in vitro drug permeation profiles, 
irrespective of drug mass-concentrations and formulation type (Figure 23), whereas the 
regenerated cellulose dialysis membrane was able to differentiate between these variable 
factors (Figure 24), assuming the molecular weight cut off parameter is the sole determination 
feature for drug partitioning in this scenario. These apparent differences in permeation 
behaviour across the selected synthetic membranes can be attributed to differences in intrinsic 
properties of the membrane itself, i.e. membrane thickness, molecular-weight cut off range, 
nominal pore size and porosity.  
Even though it is evident that the use of synthetic membranes as “representative” airway 
epithelial barriers can be used to collate useful information regarding drug release and 
permeability characteristics, it should be considered as a simplified approach with several 
limitations, i.e. lack in surface composition and lipophilicity properties. Specifically, of the two 
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synthetic membranes selected in this Chapter, the regenerated cellulose dialysis membrane 
better resembles in vitro Calu-3 transport profiles for both formulations (Figure 22), potentially 
being the more “representative” membrane out of the two for nebulised ciprofloxacin drug. 
This similarity in profiles could be due Calu-3 monolayers exhibiting tighter pore sizes, which 
may reflect the tighter partitioning behaviour when using the dialysis membrane.  
Despite the use of a well-differentiated and characterised Calu-3 cell-line used to model 
epithelial transport behaviour in vitro, this set up does not take into account other clearance 
mechanisms such as mucociliary escalator, cough mechanisms, phagocytosis by macrophages, 
and metabolism; however from a research stand point, this novel cell-based upper airway 
model closely mimics the in vivo human physiology, compared to conventional cascade 
impactors and therefore allows more realistic information to be drawn regarding drug 
permeation and transport behaviour. 
 
4.3 Summary  
 
The successful application of a physiologically-relevant cell-based model used to mimic drug 
dissolution, epithelial transport and consequently absorption characteristics depends on how 
closely the model can mimic in vivo properties. This Chapter described the extension and 
application of a unique in vitro cell-based upper airway model intended to mimic the human 
environment and study the pulmonary fate of OIPs. Through this unique approach, in vitro drug 
permeation and transport of two nebulised ciprofloxacin formulations has shown to differ 
kinetically in terms of drug mass-concentration, formulation type and most importantly, the 
selected physical barrier used to partition the apical and basolateral compartment.  
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In conclusion, it is important to understand how these inhaled aerosols interact at the airway 
epithelia, especially for poorly soluble drugs or for complex, controlled-release dosage 
formulation and its role on the overall efficacy and therapeutic ratios of the treatment regimen.  
 
 
Summary and Future Directions  
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CHAPTER 5 
Summary and Future Directions  
 
5.1 Summary  
 
This thesis describes the development and validation of a new hybrid in vitro approach used to 
characterise realistic airway deposition and the events following deposition of aerosols at the 
epithelia. Deposition experiments were carried out in a modified version of the medium-sized 
VCU MT – TB airway model, initially developed by researchers from VCU using anatomical 
data of the respiratory tract of healthy normal adults. The airway model was intentionally 
modified to accommodate Calu-3 monolayers cells cultured onto Snapwell inserts within the 
model for the collection of aerosols.  
Fundamentally, it was important to place the inserts at a region within the model to ensure 
sufficient drug collection for analysis, without causing significant changes to airway deposition 
behaviour. As described in Chapter 2, two cavities were placed at the first bifurcation region 
in the TB airway model, one at the front and one at the back. This has resulted in an increase 
of 1.0 % in total recovered dose in the TB model, in which we have concluded acceptable since 
this increase is expected to overlap with the large lung deposition variations seen in healthy 
patients.  
Therefore, as a proof-of-concept study, since culturing cells onto the synthetic membranes is a 
time-consuming procedure, we initially wanted to verify and validate the modified airway, 
when coupled with the Snapwell test system can be used as a hybrid in vitro tool for drug 
permeation analysis. In Chapter 3, we explored this concept by assessing different permeable 
membrane materials and evaluated how different experimental parameters, i.e., aerosol 
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collection method and presence of a stirrer in the receptor compartment would influence the 
rate and extent of drug permeation behaviour in vivo. Although the synthetic membranes do 
not resemble the complex structure of the epithelial airway barrier, inferences regarding drug 
permeability behaviour for aerosolised drug within a representative physical airway model can 
be made using this novel in vitro set up. Overall, we have concluded that this in vitro hybrid 
approach proved to be feasible with a high-dose ciprofloxacin solution formulation, when 
nebulised for a total duration of 5 minutes.  
This hybrid approach was then extended to assess in vitro drug dissolution into, and subsequent 
cellular transport behaviour across cultured Calu-3 monolayers of deposited aerosols collected 
in the proposed modified airway model. To assess the feasibility and discriminatory ability of 
this hybrid approach, two different ciprofloxacin formulations were used – an aqueous and a 
liposomal formulation. A compromise had to be made between total nebulisation duration and 
the overall integrity of monolayers following air exposure, since longer nebulisation times 
could potentially induce shear stresses onto the monolayer, compromising barrier integrity and 
tight junction properties, hence affecting drug permeation and transport behaviour. In Chapter 
4, the total nebulisation duration was decreased from 5 minutes to either 3 minutes or 1 minute. 
Irrespective of nebulisation time, no apparent changes in Papp was observed when compared to 
untreated conditions, though a significant decrease in TEER measurements were observed 
when nebulising the two formulations at longer durations. Overall, we have concluded that 
TEER is a simple and indirect method used to assess epithelial monolayer formation and 
integrity, rather than differences in paracellular permeability, or changes in pore sizes. 
Interesting, the dialysis membrane acted as the “most representative” physical barrier to model 
in vitro transport and drug permeation behaviour of deposited ciprofloxacin droplets on the 
Calu-3 cell-line. Using representative membranes as a quick and reproducible screening tool 
would complement cellular uptake studies in future studies.  
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In conclusion, the number of in vitro tools used to investigate airway deposition and post-
deposition behaviour of pharmaceutical aerosols is enormous and still increasing. With this 
thesis, new representative in vitro test methods and approaches have been proposed which have 
shown great promise as in vivo estimates. It is to be hoped that such can be used as potential 
screening tools for head-to-head comparative studies without resorting to expensive clinical 
trials and animal testing, as well as a foundation for the design of new inhalation platforms 
with improved performance efficiency and reproducibility. 
 
5.2 Future Directions 
 
One of the acknowledged limitations of this thesis is that the method of establishing and 
validating a simple yet practical approach used to characterise in vitro realistic deposition and 
the events following airway deposition have heavily relied on ciprofloxacin as the drug model, 
administered from the commercially-available PARI nebuliser. To further assess the method’s 
robustness, it would be advantageous to evaluate other commonly-used drug candidates (i.e., 
poorly-soluble corticosteroids) delivered across different inhaler platforms (i.e., DPI, MDIs, 
and add-on devices such as spacers). In this framework, differences and/or similarities in in 
vitro airway deposition behaviour across different drug candidates and inhaler device platforms 
may be observed, as well as the mechanisms underlying drug dissolution and cellular transport 
profiles of inhaled, deposited aerosols. Leading to this, the developmental scientist may further 
refine the formulation excipients and/or via aerosol generation mechanisms to improve the 
overall performance efficiency of the treatment regime.  
Another stimulating avenue for future investigation would be to assess different cell-line 
models to better understand the underlying mechanisms governing pulmonary absorption of 
inhaled aerosols. Up to this point, the Calu-3 cell-line was selected due to it being a similar 
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morphology to bronchial epithelial cells in vivo. Using different cell-lines (i.e., immortalised 
versus primary cells, healthy versus diseased cell models) which exhibit different polarised cell 
layers with different functional tight junctions and transporter proteins would be another means 
to assess the method’s feasibility. Such approaches can be utilised to better understand lung 
retention properties and pulmonary half-life owing to the complex interactions with the 
deposited aerosols and airway epithelia. 
As noted earlier, ciprofloxacin drug was nebulised into the modified airway model using 
ambient air at a constant flow rate of 15 L/min. Another potential area for future research is to 
test the hybrid model across a range of representative inspiratory flow rates, i.e., sampling at 
higher, as well as variable flow rates using a breath simulator at warm, humid conditions to 
mimic patient conditions. Such studies will provide insightful observations pertaining ranges 
in airway deposition behaviour across different air flow rates, as well as provide a better 
understanding in epithelial barrier dysfunction in response to dynamic sheer stresses from the 
air flow. Such testing regimes will provide further insight into the method’s capability in terms 
of acceptable testing conditions (intensity and duration of flow rate).  
Lastly, as differences in airway geometry would result in differences in drug deposition 
patterns, expanding this hybrid concept to the “large” and “small” VCU representative airway 
models (as shown in Chapter 1, Figure 6) would provide valuable information as to how 
structural differences in airway would affect how much drug could be collected onto the 
Snapwell inserts. Additionally, expanding the model to look at the lower region of the lungs is 
another interesting avenue to delve into; however, the challenging aspect to this is fitting the 
Snapwell insert at these small regions.  
By acknowledging the existing limitations and examining future investigations to address these 
boundaries, it is hoped that the working foundations of this thesis can be used to better 
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understand airway deposition of inhaled pharmaceutical aerosols in a more realistic manner, 
and the events following airway deposition at the epithelial level.
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